Multidrug-resistant enterobacterales in Oman :  molecular epidemiology and therapeutic insights by Al-Farsi, Hissa M.
From the DEPARTMENT OF LABORATORY MEDICINE 
Karolinska Institutet, Stockholm, Sweden 
MULTIDRUG-RESISTANT ENTEROBACTERALES IN 







































Cover image: A scanning electron microscopic (SEM) of extended-spectrum β-lactamase-
producing (ESBL) Escherichia coli. The image was created by Alissa Eckert (2013) and 
obtained from the Public Health Image Library (PHIL) with no copyright restrictions. 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by US-AB, Stockholm, Sweden. 
© Hissa M. Al-Farsi, 2021 
ISBN 978-91-8016-088-9  
Multidrug-resistant Enterobacterales in Oman:  
Molecular Epidemiology and Therapeutic Insights 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Hissa M. Al-Farsi 
Principal Supervisor: 
Prof. Christian Giske 
Karolinska Institutet 
Department of Laboratory Medicine 
Division of Clinical Microbiology 
 
Co-supervisor(s): 
Assoc. Prof. Peter Bergman 
Karolinska Institutet 
Department of Laboratory Medicine 
Division of Clinical Microbiology 
 
Dr. Maarten Coorens 
Karolinska University Hospital 
Department of clinical Microbiology 
 
Dr. Saleh Al-Azri  
Ministry of Health 
Central Public Health Laboratories, 
Muscat, Oman. 
 
Dr. Amina Al-Jardani  
Ministry of Health 




Dr. Teresa Coque  
Ramón y Cajal Institute for Bio Health Research 
(IRYCIS), Madrid, Spain. 
Department of Microbiology 
Division of Microbial Biology and Infections  
 
Examination Board: 
Assoc. Prof. Åsa Sjöling 
Karolinska Institutet 
Department of Microbiology, Tumor and Cell 
Biology. Stockholm, Sweden. 
 
Prof. Mikael Rhen  
Karolinska Institutet 
Department of Microbiology, Tumor and Cell 
Biology, Stockholm, Sweden. 
 
Prof. Ann-Beth Jonsson 
Stockholm University  
Department of Molecular Biosciences, The 

















                  To the loud peacemakers 
 
                                        paving the way for 
                                                      



























































The Red Queen told Alice 
 
“ Now, here, you see, it takes all the running you can do, to keep 
in the same place” 
              
 
 - Lewis Carroll 
 




































The spread of antibiotic resistance is a concerning issue causing limited treatment options for 
bacterial infections, particularly with Gram-negative bacteria. Surveillance and 
epidemiological studies help to  determine the magnitude of the problem as well as to 
establish early measures to slow down the spread of resistance and consequently increase 
antibiotic lifespan. Currently, there is a visible paucity of published data about resistance 
from the Arabian Peninsula. In this thesis, we studied a collection of carbapenem non-
susceptible E. coli (n=35) and K. pneumoniae (n=237) isolated in 2015 from various hospitals 
in Oman. We aimed at identifying resistance mechanisms, mapping the bacterial population 
structure, investigating bacterial fitness, and studying potential treatment options available to 
tackle infections caused by such multidrug-resistant strains. These aims were addressed in 
five papers as discussed below.   
 
NDM and OXA-48 were the only carbapenemases we found in this collection, both among 
E. coli (Paper I) and K. pneumoniae (Paper II). The pattern of resistance among the isolates 
from Arabian Peninsula mimics the pattern reported from the Indian subcontinent, most 
likely due to the close  socioeconomic interactions between them. Both regions lack KPC 
enzymes, which are commonly seen in China and the US from strains belong to ST11 and 
ST258, respectively. Despite ST11 being predominant in this collection, we did not detect 
KPC. Yet,  we detected a high-risk clone of  E. coli, ST131-H30Rx-CTX-M-15. Additionally, 
we identified newly emerging clones of K. pneumoniae and E. coli such as ST231 and 
ST1193-H64RxC, respectively. 
 
Nearly 10% of the K. pneumoniae isolates in our collection were colistin resistant which 
prompted us to study the mechanisms of colistin resistance (Paper III). MgrB-inactivation 
by insertion elements was seen in 8 isolates while other mutations were seen in other 
chromosomal genes known to be involved in colistin resistance e.g.  pmrB, phoPQ and crrB. 
However, we did not detect mcr genes. Collectively, the genetic alterations are thought to 
reduce the net negative charge in bacterial cell wall, hence lowering the binding affinity of 
colistin. Our data underscores that there is no reduction in the surface charge in colistin-
resistant K. pneumoniae, due to the MgrB-insertion (Paper IV). The genetic alteration might 
lead to other structural changes in the cell wall such as altering hydrophobicity, which 
required further investigation. Also, our data shows no difference in the survival rates of 
colistin resistant and susceptible strains in blood, serum and zebrafish model. Thus, gaining 
resistance against colistin does not infer a fitness cost in K. pneumoniae with MgrB-insertion 
(Paper IV). Additionally, colistin and LL-37 share similar binding mechanism which suggest 
there might be a cross-resistance between them. Our data supported this hypothesis, but only 
at high concentrations of LL-37 ( ≥ 50 mg/L) (Paper IV).     
 
Finally, we studied available options to treat infections caused by multidrug-resistant strains. 
Combining colistin and rifampicin showed good in vitro activity against multidrug-resistant 
strains of E. coli (Paper V) and K. pneumoniae (Paper III). To summarise, we conducted  
comprehensive genomic analysis of E. coli and K. pneumoniae isolates from Oman to reveal 
the resistance mechanism, their impact on bacterial cell structural and if there is a fitness cost 
inferred by the resistance mechanisms. Finally, we studied combination therapy as an 
available option at hand for tackling infections caused by multidrug-resistant strains.   
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LIST OF ABBREVIATIONS 
 
AmpC Ampicillinase type C  
AMPs Antimicrobial peptides 
 OXA Oxacillinase 
ArnT Aminoarabinose  glycosyotransferase 
BCA Background corrected absorption  
CaMHB Cation-adjusted media CaMHB 
Cas  CRISPR-associated genes  
CFU Colony-forming unit   
CMS Colistinmethate sodium 
Col-R Colistin resistant 
Col-S Colistin susceptible 
CP-CRE Carbapenemase producing-CRE  
CRE Carbapenem-resistant Enterobacterales 
CRISPR Cluster regularly interspaced short palindromic repeats 
DIW Deionized water  
DR Direct repeats  
EptA phosphoethanolamine transferase 
ESBL Extended-spectrum β-lactamase  
GlcNAc N-acetylglucosamine 
HGT Horizontal gene transfer 
Hi-RC High-risk clone 
HMM High molecular mass  
IM Inner membrane  
IMP Imipenemase 
IS Insertion elements 
Kdo 3-deoxy-D-manno-oct-2-ulosonic acid 
KPC Klebsiella pneumoniae carbapenmase 
Arn Aminoarabinose (4-amino-4-deoxy-L-arabinose ) 
LB Lysogeny broth  
LPS Lipopolysaccharides  
MBL Metallo-β-lactamase  
MCR Mobile colistin resistant protein 
MHB Mueller Hinton Broth 
MIC Minimum inhibitory concentration 
MLST Multilocus sequence typing 
MRSA Methicillin resistant S. aureus 
MurNAc N-acetylmuramic acid 
NDM New Delhi metallo-β-lactamase  
OM Outer membrane 
OMP Outer membrane proteins 
PBP   Penicillin binding proteins  
PBS Phosphate buffered saline  
PG Peptidoglycan 
RPMI1640 Culture medium developed by Roswell Park Memorial Institute 
SEM Scanning electron microscopy 
SNP Single nucleotide polymorphism 
ST Sequence type 
TEM Transmission electron microscopy   
VIM Verona integron-brone metallo- β-lactamase  
VRSA  Vancomycin resistant S. aureus 
WGS Whole genome sequencing  

















Long time ago, I thought it would be fun to attend a military training, so I did. I joined Nizwa 
military academic school in Oman. No reasons were required there to yell at someone or treat 
them like a slave. If the trainer did not like the way you walk, you might end having an extra 
round (duplication) at the peak of the summer in July where temperature normally goes 
beyond 40°C. When we were out for the physical training, the cells were inspected. If they 
thought, the beds were not tidy, the cell will be turned upside down, the dustbin will be 
emptied in the sleeping mattress. The number of participants dropped as some could not take 
it anymore. I left the campus as well but only when the training period was over with ashy 
skin and a pride being one of those who managed to stand the pressure.  
The reason why me and others survived was not only attributed to us as individuals despite 
that play a role as well since not all participants managed to finish the course. The main factor 
was the induced pressure was not strong enough to break us but enough to stretch us and turn 
us resilient. This is a sort of stress with good intention called hormesis. I tried to create such 
positive stress throughout my PhD study by attending courses and conferences. I know it is 
a motivation factor to go forward.  
This is what we do with bacteria when we start taking an antibiotic yet we do not comply 
with full treatment course. Bacteria become resilient as much as I did during the military 
training. Hormetic effect explains what happens during the exposure to increment but low 
dose of stress. Yet, what does happen if we withdraw the stress? After the military training I 
reverted back to my old habits, no more waking up at 4:00 am to exercise yet still tidy my 
bed religiously before I leave home! Why did I carry some of the habits but not others? It 
depends on the cost I pay to maintain them and the rewards I gain from carrying them.  
Generally, we as humans assume bacteria do not anticipate the future as we do but live in the 
present moment as we fail to do. We assume as such bacteria will revert to be susceptible as 
they lack the sense of foreseeing the future. A study  showed that after 50% decrease in the 
consumption of certain macrolide in Finland,  there was 50% decrease in the prevalence of 
erythromycin resistance in Streptococcus pyogenes between 1991 to 19961. While 
withdrawal of cotrimoxazole and streptomycin in UK did not affect the prevalence of 
sulfamethoxazole and streptomycin resistance in E. coli 2. This variation might be attributed 
to the cost paid by bacteria to keep resistance attributes despite the absence of antibiotic 
pressure. Much goes with the context of “The red Queen Theory” which was introduced by 
Van Valen in 1973 that implies organisms must evolve and adapt to new challenges not to 






1.1  Multidrug resistance as a public health issue 
1.1.1 The pride comes before the fall  
Not quite far, 100 years ago, we had no tools to fight back bacterial infections. We look at 
pregnancy as a safe biological process to bring new lives now. Yet back then, it was a 
biological process to trade mother’s life for infant’s life due to many reasons including failure 
to treat post-partum infections. We as humans, did not have any tools to handle these 
infections until someone thought outside the box.  
Ingaz Philipp Semmelweis proposed the practice of washing hands with chlorinated lime 
solution in 1847 to tackle the increased incidence of puerperal fever which was the main 
cause of mortality in obstetrical clinics. He published a book “Etiology, Concept and 
Prophylaxis of Childbed Fever” and showed results to support his recommendation but was 
faced with rejection by the medical community then as they felt offended to be asked to wash 
their hands. He suffered from mental breakdown from stress. In 1865, he passed away from 
a gangrenous wound, due to infection after being beaten at an age of 473. These challenges 
from the past continue until the present days. During the COVID-19 pandemic in 2020, 
following the recommendation of wearing a mask and keeping physical distance, as simple 
as they sound, were hard to implement. All in all, we see that relying on human behaviour as 
a tool to fight infectious diseases is quite hard to sustain as such more reliable tools are 
required such as antibiotics and vaccines. 
At the beginning of 1910s, Paul Ehrlich introduced salvarsan as the first antimicrobial agent. 
It was used to treat syphilis4. Followed by Fleming’s discovery of penicillin in 1928 and 
many more antibiotics that gave us quite plenty of tools to fight bacterial infections and save 
lives. In 1967, a remarkable announcement came from U.S. Surgeon General William 
Stewart “The time has come to close the book on infectious diseases”5. That pride with plenty 
of antibiotics at hand just faded after 1970s, since we entered a dry innovation season, while 
bacteria fought back strongly. 
1.1.2 The bright past just passed 
The first serious battle we had was MRSA (Methicillin resistant S. aureus) in the beginning 
of 1970s against Gram-positive bacteria. We opened our antibiotic closet looking for a 
solution. Vancomycin, which was first sold in 1954 could be a desperate choice despite the 
known side effects such as nephrotoxicity (Figure 1). Luckily, a purified form of vancomycin 
was produced with less toxicity. In 1996, bacteria went ahead again in a second battle known 
as VRSA (vancomycin resistant S. aureus). After this initial nightmare two new antibiotics 
were introduced; linezolid and daptomycin in 2000 and 2003, respectively (Figure 1). As we 
humans thought we had won the battle, Gram-negative bacteria pressed the replay button. 
 
4 
Gram-negative bacteria are harder to treat since they have an extra protection layer in their 
cell wall which is a challenge for drugs to pass. Besides, the transmission of resistance genes 
between different species of Gram-negative bacteria is frequently high as compared to Gram-
positive bacteria. Despite plasmid-encoded penicillinase was first been observed in 
Staphylococci, there were limited intra-species transmission compared to Gram-negative 
bacteria6.  
The first clinical impact of resistance in Gram-negative bacteria to β-lactam was in 1974 by 
penicillinases, when researchers reported ampicillin treatment failure in meningitis patients 
due to Haemophilus influenzae type b producing TEM β-lactamase7. The plasmid encoding 
blaTEM was transmitted to Neisseria gonorrhoeae8. This resistance mechanism spread widely 
between different continents due to naval activity between Asia, western Africa and 
England9. The drug development industry came up with a set of 24 novel modified β-lactams 
with extended-spectrum including β-lactamase inhibitors, third generation cephalosporins, 
monobactams, and carbapenems in the 1980s9.  
 
 
Figure 1. Timeline for key antibiotics. For each antibiotic three dates are represnted; the discovey date, the 
date when the antibiotic was used clinically and the date when resistance spread.  The clinical use of polymyxin 
was discontinued for concern regarding side effects by 1970s. However, due to lack of treatment options, the 
drug was re-used again clinically in mid-1990s. Malacidin and teixobactin are not yet approved. Cefiderocol 
was recently approved in US (2019) and in Europe (2020). Adapted from Gautam and Sommer5. Copyright 




Soon bacteria responded by producing extended-spectrum β-lactamases (ESBLs). The first 
ESBL in a clinical isolate was reported in 1983 from Klebsiella ozaenae in Germany10. By 
the mid-1980s, outbreaks of Enterobacterales producing ESBL were reported in France due 
to TEM derived CTX-1 and CAZ-1 enzymes. As their names imply CTX-1 conferred more 
resistance to cefotaxime whereas CAZ-1 was more active against ceftazidime11. In the early 
1990s, CTX-M-type ESBLs emerged and by the mid-1990s they caused large outbreaks of 
Salmonella Typhimurium. More variants of CTX-types were detected including CTX-M-15 
which proved to be a game changer regarding the spread of ESBL globally. By the 2000s it 
became the predominant type of ESBL globally, replacing the TEM- and SHV-derived 
ESBLs12. The access to the drug class carbapenems still kept us quite ahead of the bacteria. 
However, the frequent use of carbapenems against ESBL-producers predicted carbapenem 
resistance is the upcoming storm. 
Type C ampicillinase (AmpC) enzyme was first discovered by Swedish investigators in 1940 
in E. coli. As the name implies, it was initially thought to only affect ampicillin13. Another 
report of this enzyme in Pseudomonas was published in 196514. Yet, it grabbed more 
attention in 1976 when it  was reported in the UK15. Now we know it is capable of not only 
hydrolysing penicillins but also cephalosporins, cephamycins and monobactams, leaving 
only carbapenems unaffected. However, AmpC could even hydrolyse carbapenems, if 
combined with other mechanisms such as porin loss16. The threat was magnified when 
AmpC-type enzymes were detected on plasmids in 1990, as this would enhance its propensity 
to spread9.  
The first carbapenemase was isolated from Pseudomonas in Japan in 1990 and was named 
impenemase (IMP)17. Followed by the detection of Verona integron-borne metallo-β-
lactamase (VIM) in Italy from Pseudomonas as well in 199718. More notorious types of 
carbapenemases were detected later such as the Klebsiella pneumoniae carbapenemase 
(KPC), oxacillin-hydrolyzing carbapenemase (OXA-type) and New Delhi metallo-β-
lactamase (NDM)9. Here, we were literally trapped. We went back to our antibiotic closet 
and took colistin out despite its limitation in both efficacy and toxicity19. As such colistin 
resistance was foreseen. Multiple outbreaks were reported with colistin and carbapenem 
resistance Enterobacterales (CCRE)20. Bacteria were again ahead of humans. 
1.1.3 Back to the future 
We still lack a realistic estimation of lives lost yearly due to antibiotic resistance as the 
number is overshadowed by main cause of death. For example, a cancer-patient if expired 
due to a struggle with infection caused by antibiotic resistant bacteria, often the case will be 
counted as a death caused by cancer rather than antibiotic resistance. A similar scenario is 
seen in HIV and transplant patients. Thus, the numbers of death due to antibiotic resistance 
is far underestimated. Also, many life-saving surgical procedures would cease if we have no 
effective antibiotics to treat the inevitable infections at surgical sites which adds up in 
underestimating the impact of resistance in public health. This will not only mask the burden 
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but will have a crucial impact on allocated resources for intervention. Consequently, the 
antibiotic resistance issue remains less studied with a big knowledge gap yet to be filled.  
A recent report in 2019 estimated the number of deaths attributed to antibiotic resistance only 
in the US, to be more than 35,000 while the number of infections was estimated to be more 
than 2.8 million each year21. This gives an estimation of less than 0.001% death rate. On the 
other hand, a study conducted in 2014 estimated the number of death due to antimicrobial 
drugs resistance, including antibiotics but not limited to them, would be 10 million yearly by 
205022. Yet, they estimated the combined deaths caused by road traffic injuries, cancer and 
diabetes to be around 11 million annually in 205022,23. Bearing in mind diabetes, cancer and 
road injuries were listed within the top 10 causes of death in 2019 globally24. The paper 
received criticisms regarding uncertainty of assumptions to determine the rate of incidence, 
as it compiled two sets of data each of them used distinct assumptions and covered particular 
sources of infections e.g. community versus hospital acquired infections25. One advantage of 
the study was that it considered the impact of resistance on other medical procedures as a 
secondary effect for the problem. A better approach would be to lay down the estimation 
from each study separately rather than the risk of combining both, despite the methodological 
variations used in each. Also, it would be more informative to break the numbers down rather 
than counting HIV, malaria and TB. We know these diseases already cause high mortality. 
Yet, researchers in antibiotic resistance are looking for death cases caused by antibiotic 
resistance specifically. Additionally, listing death caused by primary or secondary attributes 
separately will give better insight to the magnitude of the problem. However, no doubt the 
report drove public attention and was a kick-off to think thoroughly about how to estimate 
the burden of antibiotic resistance and improve data collection as well as analysis in this 
regard. 
Additionally, political barriers and national health policy are other challenges. This has been 
evident after the discovery of NDM and the reaction from the Indian government to restrict 
sending biological samples abroad for research purposes. They saw NDM as a stigmatising 
factor to their country, especially after naming the enzyme by the capital city in India “New 
Delhi”. This impacted tourism which led to economic consequences26. Now, it is quite 
difficult to ship biological samples from India for research purposes and barriers to carry out 
epidemiological studies are becoming high to pass. Since it is a multifactorial issue with 
economic and political complications, the nomenclature of new genes could be revisited to 
minimise provoking logistic barriers for future studies. The awareness NDM brought to this 
matter was manifested by the neutral name given to the mobile colistin resistance (mcr) gene 
isolated from China in collaboration with some investigators who isolated blaNDM 
previously27,28.  
Antibiotics are social drugs with respect to their consumption by an individual will impact 
their effectiveness for others. Unlike the drugs that control high blood pressure or cholesterol 
level for example, where there is no such impact between individual consumption and long-
term efficacy29. This creates another challenge related to social and cultural behaviours 
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towards consumption in different countries. Recent studies linked the increase of living 
standard in low-income countries to the increase of antibiotic consumption30,31. This could 
be due to the search for a fast fix that is affordable rather than the more time-consuming 
solution such as building infrastructure for diagnostic facilities which enhance identifying 
resistant strains prior to antibiotics consumption. Moreover, unregulated policy in private 
health sectors could play a role, since they go immediately to the last treatment option to 
satisfy the customer/patient and increase their reputation to cure infections fast andthereby 
increasing their profits. In less economically fortunate nations the scenario differs, since the 
majority of people cannot afford the expenses of health services such as visiting clinic and 
performing diagnostic tests prior to buying the lifesaving antibiotic. Thus, implementing the 
compulsory regulation for diagnosis and prescription prior to selling antibiotics might 
prolong antibiotics lifespan but might indirectly cause loss of lives for those who cannot 
afford paying for such services. Particularly, in the absence of social benefits to protect the 
vulnerable groups. As we see, despite the global impact of the issue a “one size fits all”-
solution is not achievable and a tailored solution for each nation is needed bearing in mind 
the local socioeconomic structure. 
Additionally, the increase of income leads to higher demands for food consumption. 
Consequently,  the use of antibiotics in farming and agriculture are increasing to cover the 
high demand for proteins30. The world health organisation (WHO) introduced the one health 
concept to tackle this issue. Furthermore, the concept was nourished by other programs such 
as Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). It implies, the issue 
of antibiotic resistance requires a collaborative attention from three sectors (human health, 
animal and environment) as the consumption of antibiotics in any of them will impact the 
utility and effectiveness of the drug in human health32. This expands the concept of antibiotic 
from a social drug into a universal drug.  
As researchers in the field of antibiotic resistance, we acknowledge having a problem that 
requires intervention. Simultaneously, we acknowledge the multifactorial challenges in 
estimating the real burden of resistance compared for example to other infectious diseases 
such as HIV and malaria. I trust that epidemiological studies with ethical permits such as the 
one presented herein will help mapping the burden of antibiotic resistance. Besides,  
understanding the evolution of resistance may extend the life of the currently available 
antibiotics and slow down resistance. Consequently, this would reduce the ultimate cost paid 
by patients and society. 
1.2 Antibiotics: Action and resistance 
Antibiotics can be classified into different classes according to their chemical structures or 
mechanisms of action. Based on their targets, antibiotics could be divided into two main 
classes. A class of drugs that inhibits intracellular reactions such as proteins or nucleic acids 
synthesis. Rifampicin and azithromycin belong to this class. The second class includes 
antibiotics that target bacterial envelope such as β-lactams and polymyxins.  
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As antibiotics have different targets, bacteria evolve to resist them differently. Some of the 
resistance mechanisms apply to a wide range of antibiotics while others are tailored for 
specific drugs based on their chemical structure or the structure of their targets. The physical 
mechanisms, also known as intrinsic mechanisms, aim to reduce antibiotics uptake through 
cell surface modification by restricting the uptake (influx) or enhancing the excretion 
(efflux). This is achieved by porins modification or efflux pumps activation, respectively. 
The specific resistance mechanisms involve modification of drug target or inactivation of the 
drug (Figure 2). An example of the former is resistance mechanism against colistin by 
altering lipid A structure whereas the production of  β-lactamase is an example of drug 
inactivation5. The general intrinsic mechanisms are mainly attributed to chromosomal genes 
while the tailored mechanisms are generally carried in transferable elements such as 
plasmids. Especially this second type of resistance creates a challenge to control infections 
as it can be transmitted both vertically and horizontally.  
During vertical gene transfer, bacteria inherit their genetic contents from parental cells in the 
previous generation whereas during horizontal gene transfer (HGT) bacteria could gain 
genetic material from unrelated bacterial cells or their surroundings. There are three 
mechanisms of HGT; transformation, transduction and conjugation. They differ in the source 
of genetic material that bacteria uptake. In transformation bacteria obtain foreign DNA from 
the environment whereas for the remaining two mechanisms DNA will be obtained from a 
donor, either a phage or a plasmid by transduction or conjugation, respectively33. Conjugation 
plays a significant role in the spread of resistance genes within and between species. Yet, 
transduction is more involved in spreading virulence genes, and it is thus far unclear to which 
extent bacteriophages contribute to spreading resistance genes.  
Most of the genes involved in polymyxin (colistin) resistance are chromosomal, which limits 
their mobilities. In contrast, genes encoding β-lactamases are frequently found in plasmids, 
which allows for easy horizontal transmission and fast spreading. Both polymyxin and β-
lactam antibiotics act by interfering with the biosynthesis of the outer membrane and the cell 
wall, respectively. Polymyxins compete with and replace divalent cations that usually bring 
nascent lipid A molecules together physically, while β-lactams chemically inactivate the 
enzyme responsible for cross-linking nascent peptidoglycans. The following section will 
describe different components within the bacterial envelope which are used as targets by 






Figure 2. Mechanisms of antibiotic resistnce. Bacteria aquire antibiotic resistance by modifying their DNA. 
The genetic alteration could cause either a general mechanism of resistance such as porin loss or activation of 
efflux pump. Alternatively, mutated bacteria could gain more specific mechanisms of resistance, for example 
the ability to degrade antibiotics enzymatically or modify their targets so the binding would not occur. 
The cellular envelope protects bacteria from hostile factors in their environment. In Gram-
negative bacteria there are three main layers; the outer membrane (OM), the peptidoglycan 
(PG) and the cytoplasmic or inner membrane (IM). Among Gram-positive bacteria the 
envelope has only two layers consisting of a PG and an IM. Generally, Gram-negative 
bacteria are more resistant to antibiotics, due to the presence of the OM which restricts drug 
uptake. The bacterial envelope plays a key role in resistance mechanism. Thus, understanding 
the bacterial envelope is a key factor in slowing down resistance as well as developing new 
therapeutic drugs to treat infections. 
1.2.1 The outer membrane when negativity is a merit 
The outer membrane in Enterobacterales is composed of phospholipids arranged in a bilayer 
of inner symmetric leaflets and outer asymmetric leaflets. The outer leaflets are intercalated 
by lipopolysaccharides (LPS) through Van der Waals forces. In addition, the OM bilayer is 
embedded with outer membrane enzymes such as PagP and PagL in E. coli and Salmonella 
enterica, respectively. These enzymes usually regulate and modify LPS by acylation 
process34. Additionally, OM has outer membrane proteins (OMPs) such as porins which 
modify cellular permeability (Figure 3).   
1.2.1.1 Outer membrane protein: gatekeeper 
The outer membrane has β-sheet proteins which are wrapped into cylinders known as outer 
membrane proteins (OMP). The main function of OMPs is to exchange small molecules 
across outer membrane. Consequently, they enhance bacterial adaptability to various 
environments through regulating permeability. Porins are the most abundant OMPs that 
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Figure 3. Depiction of cell-envelope components. A| Cell-envelope of Gram-positive and Gram-negative 
bacteria. Gram-positve bacterium has an exposed yet thick peptidoglycan (PG) layer. Whlist Gram-negative 
bacterium protects the  PG layer by an outer membrane (OM). CAP; covalently attached protein; IMP, integral 
membrane protein; LP, lipoprotein; LTA, lipoteichoic acid; WTA, wall teichoic acid. Adapted with permission 
from Silhavy et al.35 Copyright (2010) Cold Spring Harbor Laboratory Press. B| Porin and efflux pump are 
involved in antibiotic resistance by altering cellular influx and efflux, respectively. Efflux pump consists of 
three main components; an outer membrane protein (OMP), a membrane fusion proteins (MFP) and a pump as 
an inner membrane (IM) transporter. LPS; Lipopolysaccharides. Adapted with permission from Li et al.36 
Copyright (2015) American Society for Microbiology. C| Chemical structure of LPS components; lipid A, core 
oligosaccharide and O-antigen. The core oligosaccharide is located in the middle between lipid A and O-
antigen. It is attached to lipid A via Kdo (3-deoxy-D-manno-oct-2-ulosonic acid) molecule (framed in red).  
Adapted with permission from Barkleit et al.37 Copyright (2008) The Royal Society of Chemistry. D| Final steps 
involved in PG synthesis require two types of high-molecular-mass penicillin-binding proteins (HMM PBP). 
Glycosyltransferase (HMM PBP) binds to the pre-formed disaccharide units; N-acetylglucosamine (GlcNAc) 
and N-acetylmuramic acid (MurNAc) to form a linear glycan layer. While transpeptidase (HMM PBP) cross-
links glycan linear layers by utilising acyl-D-alanine-D-alanine (D-Ala-D-Ala) in the side chain of a MurNAc 
unit as a substrate (Figure 5). Thus linking 2 MurNAc units to form a solid mesh-like structure. Adapted with 
permission from Dik et al.38 Copyright (2018) American Chemical Society. 
affect membrane permeability. Thus, genetic alterations or total loss of porins will enhance 
bacterial resistance to antibiotics. For example, it is well established that alteration or total 
loss of specific porins in E. coli (OmpF and OmpC) or K. pneumoniae (OmpK35 and 
OmpK36) causes resistance to a wide range of antibiotics including β-lactams39. Porins 
alteration could be achieved by gaining mutations directly into genes encoding porins or the 
regulatory genes such as envZ and ompR in E. coli40.  
Additionally, outer membrane vesicles (OMV) are produced by most Gram-negative 
bacteria. These vesicles are released from the cell envelope. They are simply sacs with high 
profile of proteins and lipids and have been linked to antimicrobial resistance due to their 
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Besides the role of the outer membrane in antibiotic resistance, it can enhance bacterial 
pathogenicity. For example, OmpX in E. coli and OmpK17 in K. pneumoniae are known to 
help in adhesion and invasion as well as promoting bacterial resistance to serum by 
inactivating the complement system41. Also, OmpA in K. pneumoniae can clear infection and 
proposed as a potential target for vaccine development42. The loss of OmpA in K. 
pneumoniae has been found to reduce capsule expression thereby increase susceptibility to 
polymyxin43. In the other hand, OMPs play an indirect role in active excretion of harmful 
molecules such as antibiotics as being part of the efflux-pump system. 
1.2.1.2 Efflux pump: dealing with gatecrashers 
The efflux pump consists of three units; an inner membrane transporter (pump), a periplasmic 
fusion protein and an outer membrane (OM) channel protein (Figure 3B). The main function 
of the efflux pump is to expel toxic substances such as antibiotic from passing to bacterial 
cell. Also, it plays a role in virulence mainly by enhancing colonization through protecting 
bacteria from antimicrobial compounds present naturally in mucosal surfaces. For example, 
over expression of  the AcrAB-TolC pump is known to cause resistance against β-lactams 
and polymyxins in E. coli and K. pneumoniae40,44,45. 
1.2.1.3 Lipopolysaccharides (LPS): polymyxin target 
Structurally, LPS is composed of three units; the hydrophobic lipid A, two hydrophilic chains 
of oligosaccharides and O-antigen. The conserved lipid A anchors LPS in the outer leaflets 
of outer membrane enhancing its asymmetric structure compared to the symmetric structure 
of the inner leaflets. The oligosaccharide is located in the middle between lipid A and O-
antigen and arranged into two cores; the inner being attached to lipid A and made of 3-deoxy-
D-manno-oct-2-ulosonic acid (Kdo), while the outer core being attached to the O-antigen and  
is made up of variable hydrophilic repeated saccharide units34,46,47(Figure 3C). 
LPS enhances the anionic charge of the outer membrane due to the presence of phosphoester 
moieties in lipid A as well as carboxylate and phosphate groups within the core 
oligosaccharide and the O-antigen units46. Thus, LPS restricts the entry of big negatively 
charged molecules. Besides, LPS affects the bacterial ability to respond to the immune 
system and plays a role in adhesions47.  
Since LPS is an important component with multiple functions, bacteria possess many 
enzymes to modify its features as an adaptation process to different surrounding34. LPS 
synthesis starts with the Raetz pathway in the inner membrane facing the cytoplasm. It 
involves a series of reactions with highly conserved enzymes. Eventually, LPS is transported 
across the inner membrane to the outer membrane. However, adjustment of LPS contents 
continues even when it reaches its final destination. This is achieved through modification of 
the variable O-antigens or mainly the conservative lipid A34,47,48. 
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Structurally, lipid A is an anionic hydrophobic disaccharide of glucosamine (GlcN) with four 
to seven acyl chains (fatty acids) and phosphate groups. It is attached to the oligosaccharide 
by two molecules of Kdo sugars49 (Figure 3C). Divalent cations (magnesium and calcium) 
attach to phosphate groups in lipid A and bridge adjacent LPS molecules to add stability50. 
Lipid A exhibits different degrees of acetylation and phosphorylation in different bacteria. 
The extent of phosphorylation determines the net charge of the membrane. This is affected 
by different mechanisms like masking phosphate groups from lipid A with positively charged 
molecules such as phosphoethanolamine (pEtN by EptA) and 4-amino-4-deoxy-L-arabinose 
(Arn by ArnT) or adding more phosphate groups to increase negativity via LpxT34. The net 
charge is targeted as a binding site by polymyxins and antimicrobial peptides such as LL-37. 
1.2.1.4 Polymyxin mechanism of action  
Polymyxins are cationic, hydrophobic and lipophilic molecules. The last two properties give 
polymyxins amphipathic chemophysical properties which is the core of their antibacterial 
activity46. Polymyxin, as positively charged molecule binds to the negatively charged 
phosphate group in lipid A electrostatically. The binding will consequently, displace the 
divalent cations (magnesium and calcium) from phosphate groups in lipid A which will 
disrupt outer membrane stability as these cations bridge LPS. Additionally, polymyxin 
hydrophobic regions bind to LPS. The detailed mechanism of polymyxin antibacterial 
activity is still unknown, yet we know electrostatic and hydrophobic interactions are essential 
steps in polymyxins initial encounter with the bacterial cell20,46. As such it was hypothesized 
that bacteria resist polymyxin by reducing the net negative charge of  lipid A20.   
One might wonder, if bacteria aim to reduce the net negative charge, the affinity of divalent 
cations to bind and bridge lipid A will be lost as well. To what extent these cations are 
important for the stability of bacterial cell requires more research. Clearly, there is still a gap 
in our understanding of polymyxin action and resistance mechanisms. Below the known 
mechanisms of resistance are described.  
1.2.1.5 Polymyxin mechanism of resistance 
Bacteria develop resistance against polymyxin by decreasing the net negative charge of lipid 
A. This is achieved by adding positively charged aminoarabinose (Arn) molecules (by ArnT) 
and phosphoethanolamine (pEtN) molecules (by EptA). Hence lowering the affinity of 
colistin to lipid A. The modification of LPS is upregulated by the two-component regulatory 
systems PhoPQ and PmrAB. Upregulation of these systems will increase the expression of 
genes encoding proteins for the biosynthesis of aminoarabinose and phosphoethanolamine. 
The two-component systems usually become activate in response to stimuli such as metal 
concentration or low acidity34 (Figure 4). 
The PmrAB two-component system consists of the pmrABC operon that encodes the 
membrane bound sensor kinase (PmrB), regulatory protein (PmrA) and transferase (PmrC 
also known as EptA). Low pH or high iron concentration will activate PmrB. PmrB will  
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Figure 4. Modification of lipopolysaccharides (LPS). Modification of LPS involves two-component systems; 
PhoPQ and PmrAB. They work independently or together mediated by PmrD. The activation of PhoPQ or 
PmrAB eventually reduces the net negative charge in LPS through addition of aminoarabinose (Arn) by ArnT 
(aminoarabinose transferase) enzyme (pathway indicated by green lines) or phosphoethanolamine (pEtN) by 
EptA (phosphoethanolamine transferase) enzyme (pathway indicated by red lines), respectively. Also, 
phosphated PhoP activates PagP, MgrB, PmrD and MgrR. PagP (blue lines) modifies the acyl chain in lipid A 
by the addition of palmitate chain. MgrB regulates PhoQ negatively. Mutated mgrB gene, will allow continuous 
expression of PhoPQ. Also, mutated mgrB could modify capusle structure in K. pneumoniae. Whlist PmrAB 
two-component system activates EptA (PmrC) and PmrR. The latter inactivates LpxT (purple line) to cease the 
addition of phospahte group, thus lowering the net negative charge. Binding of cationic antimicrobial peptides 
(AMPs) such as LL-37 to bacterial cell will be reduced as a consequence of LPS modification with reduced net 
negative charge. In the schematic diagram, mediatores are shaded with gray boxes. The inverted and horizontal 
“T” shape indicates inhibition. Other mechansims apart from the addition of pEtN (red), Arn (green) or 
palmitate chain via Pagb (blue) are depicted in black lines. Adapted with permission from Simposon and Trent34. 




phosphorylate and activate PmrA. Activated PmrA could upregulate PbgP (also known as 
PmrHFIJKLM or ArnBCADTEF) directly which will eventually add aminoarabinose by 
ArnT. Also, PmrA could activate PmrC (EptA) which will eventually produce 
phosphoethanolamine (pEtN). Mutated pmrB turns on these series of reactions continuously, 
independent of the external stimuli40.  
Likewise, the PhoPQ system is made up of a membrane bound sensor kinase (PhoQ) and a 
regulatory protein (PhoP). A stimulus such as low concentration of magnesium or the 
presence of antimicrobial peptides (AMPs) will activate PhoQ which will phosphorylate 
PhoP. Activated PhoP will upregulate pbgP operon either directly or indirectly by binding to 
PmrD which will eventually upregulate pbgP operon. In either way, activated pbgP will 
activate ArnT. Since PmrD is a mediator between the two-component systems PhoPQ and 
PmrAB, its activation will activate PmrAB. The later will increase the expression of pmrC 
gene which yields more pEtN. Hence, PhoPQ activation upregulates both ArnT and EptA 
enzymes. It is worth noting that PhoPQ is downregulated by the mgrB gene. Hence mutated 
mgrB will turn the PhoPQ system on and decrease the net negative charge in lipid A which 
is a common mechanism to resist colistin in K. pneuomoniae52.  
Additionally, K. pneumoniae has another two-component system known as CrrAB. It 
encodes a kinase (CrrB), a regulatory protein (CrrA) and a modulator (CrrC). It involves 
indirectly in modifying LPS by activating PmrAB via CrrC as a mediator between CrrAB 
and PmrAB. PmrA will activate PmrC and PbgP (Figure 4). Additionally, CrrC could activate  
a putative efflux pump that cause polymyxin resistance53. Still much needs to be revealed 
about what activates this system. Yet, we know once CrrAB is activated, the production of 
both aminoarbinose and phosphoethanolamine will increase40. 
Besides the activation of the two-component systems, bacteria have other ways to reduce the 
negative charge of lipid A. The expression of enzymes in the outer membrane is one of them. 
Activated PhoP regulates PagP production in E. coli which plays a role in modifying acyl 
chains by adding palmitate chain to maintain asymmetric outer membrane layer. Asymmetric 
layer protects bacteria from antibiotics entry yet without compensating much by lowering 
their nutrients uptake34,54 (Figure 4). Also, LpxT is an inner membrane enzyme responsible 
for adding phosphate group into lipid A. PmrR inhibits LpxT thereby reducing the net 
negative charge (Figure 4). Another pathway to add  phosphoethanolamine is seen in bacteria 
that carry a mobile colistin resistance (mcr) gene, with a similar effect as the chromosomal 
mutations mentioned above27 (Figure 4). Also, mutations in mgrB gene seem to modify 
capsule structure in K. pneumoniae and increase resistance to polymyxin as well as affect the 
expression55. Additionally, alterations of O-antigen such the length of the chain can induce 
polymyxin resistance. In Salmonella enterica, PmrA activates wzz gene that promotes O-





1.2.1.6 Polymyxin cross-resistance with LL-37 
The binding mechanism of colistin through electrostatic interaction with the negatively 
charged LPS resembles the mechanism used by antimicrobial peptide such as LL-37. LL-37 
is part of the innate immune system and has antimicrobial properties against a wide range of 
microbes including bacteria57. It resides in different cell types, most notably in neutrophils58. 
A concern was raised regarding the cross resistance between colistin and LL-37, since they 
have similar binding mechanism59,60. If a bacterial pathogen can resist colistin, it might 
eventually resist the killing by LL-37 which would lead them to escape host immunity (Figure 
4).  
1.2.2 Peptidoglycan when less is more: β-lactam target 
The bacterial cell wall is made of peptidoglycan (PG) in both Gram-negative and Gram-
positive bacteria. The PG layer in Gram-negative is thin (35-40 nm) and hidden beneath an 
outer membrane compared to the exposed thicker (40-60 nm) PG in Gram-positive bacteria 
(Fig 3A). Disrupting the construction of PG is the mechanism of action of β-lactam drugs. 
Hence, penicillin is more effective against Gram-positive bacteria61.  
The building unit of PG is a glycan strand which consists of an alternating saccharide of N-
acetylglucosamine (GlcNAc also known as NAG) and N-acetylmuramic acid (MurNAc also 
known as NAM). The construction of PG is a complex process involving different types of 
penicillin-binding proteins (PBPs). Two of them are of interest in this context, 
glycosyltransferase high molecular mass (HMM PBPs) and transpeptidase (HMM PBPs). 
Glycosyltransferase high molecular mass (HMM PBP) builds linear glycan strand by 
covalently linking the two saccharides units (GlcNAc and MurNAc) via β-1,4-glycosidic 
bond. This will result in a linear glycan strand made up of disaccharides. One of them 
(MurNAc) has a stem made of pentapeptide with acyl-D-Ala-D-Ala end. Acyl-D-Ala-D-Ala 
is utilised as a substrate by transpeptidase to produce acyl enzyme with transient nature to 
cross-link two MurNAc units in different linear glycan strands forming eventually a stable 
mesh structure (Fig 3C-D). In short, glycosyltransferase creates linear glycan strand between 
GlcNAc and MurNAc, while transpeptidase cross-links two MurNAc units in different 
glycan strands to form rigid cell wall. β-lactam interferes with the cross-linking process as 
elaborated below. 
1.2.2.1  β-lactamase: when having a ring does matter 
β-lactam chemical structure mimics acyl-Ala-D-Ala, as both have a central amide bond. β-
lactam will bind and lock transpeptidase (HMM PBPs) and as such interferes with the mesh 
formation. This will prevent the final crosslinking of the nascent peptidoglycan layer (Figure 
5). Thus, structural integrity of the cell wall decreases, which results in osmotic lysis of the 




Figure 5. Mechanisms of action and resistance of β-lactam. A| Transpeptidase is a penicillin-binding protein 
(PBP). It utilises the native D-Ala-D-Ala terminal in MurNAc (N-acetylmuramic acid) saccharide as a substrate 
to produce acyl enzyme with transient nature. This eventually crosslinks with another MurNAc saccharide in a 
nascent units of peptidoglycan to form mesh-like structure. B| β-lactam, here represented by penicillin, mimics 
D-Ala-D-Ala of MurNAc molecule as both have amide bond, yet penicillin has the amide in β-lactam ring. PBP 
will bind to penicillin instead of D-Ala-D-Ala substrate, thus an irreversible complex acyl enzyme will be 
formed. This will cease the following step of cross-linking and eventually rupture the cell wall. However, in the 
presence of β-lactamase (βL), the enzyme will hydrolyse β-lactam ring rendering the drug inactive. Adapted 
with permission from Astrid Zervosen et al.62Copyright (2009) American Chemical Society.  
 
1.3 Bacterial fitness:  The cost to exist   
The most prevalent strain in nature is known as wild-type strain. Such strain fits well in nature 
as their genetic content is stable. However, under selective pressure they lack the tools to 
adapt and survive. Under such unfavourable conditions and to avoid extinction, wild-type 
strain is forced to adapt. In the pre-antibiotic era, the main challenge faced by bacteria is to 
survive in a host. Thus, the wild-type strains deviated by gaining a set of tools “virulence 
factors” that enabled them to establish an infection as well as to escape host immunity. 
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Furthermore, antibiotics added a new challenge that required a new set of tools, “resistance 
factors”. Acquiring these tools will cost wild-type a reduction in their fitness.  
Resistant strains can be weakened by altering their structures in a way to bypass antibiotic 
activity. This can lead to reduced survival strength when competing with wild-type strains in 
the absence of antibiotic33. Therefore, resistant strains usually invade immunocompromised 
patients with impaired immune systems. They are widely recognized in hospitals causing 
healthcare-associated infections compared to virulent strains that are usually associated with 
community acquired infection.  
A general model for antibiotic evolution illustrates that wild-type lineages will gradually 
evolve in three distinct stages under continuous antibiotic pressure (Figure 6A). Initially 
wild-type lineages will trade their fitness by developing new mutations for survival. At this 
initial stage, the cost of fitness has raised the hope as if the consumption of antibiotic reduced, 
the bacteria will revert back to the susceptible phenotype33. Additionally, it opens the door to 
fight bacteria not only by finding new antibiotics but also looking to enhance the immune 
system. Yet if antibiotic pressure continues, lineages will enter a second stage. There, bacteria 
would aim to stabilise the newly gained mutant-type by acquiring compensatory mutations 
to restore fitness and become as competent as the wild-type strains. Another approach to 
restore fitness is by discarding genes that do not serve the updated genetic structure. When 
such generation of resistant bacteria emerges, it is unlikely that withdrawal of antibiotic will 
revert to a susceptible phenotype33. What is more concerning is the possible marriage of both 
virulent and resistant strains. At this stage, bacteria could gain mutations that increase their 
fitness while maintaining their resistance pattern. For instance, they upgrade advantageous 
 
Figure 6.  Bacterial fitness. A| General evolutionary model for lineages under antibiotic selection. Adapted 
from Marcusson et al.(2009)63. Copyright via CC BY licence, PloS. B| Resistance to fluoroquinolones in E. 
coli. High resistance is achieved when three mutations were acquired and this causes a significant increase in 
MIC-value from 1 mg/L in double mutations (mgrR, gyrA) to >32 mg/L in the lineage with triple mutations 
(mgrR, gyrA, parC). MIC; minimum inhibatory concentration. Adapted with permission from Anderson and 
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genes to enhance invasiveness or transmission rate. In another word, this particular lineage 
becomes high risk clone (Hi-RC) such as ST131-H30Rx-CTX-M-15 in E. coli. 
An example of the model above, is the accumulative mutations seen in fluoroquinolone (FQ)-
resistant E. coli (Figure 6B). When the resistance occurred due to alteration of marR alone 
or in combination with gyrA genes, the cost of the process is high which is evidently seen 
from the margined elevation of MIC (minimum inhibitory concentration) value around 1 
mg/L, which is just enough to survive. However, the addition of a third mutation in parC 
increases both relative fitness and resistance level (MIC> 32 mg/L)33.  
A better understanding of fitness and evolution in antibiotic resistance could be gained by 
monitoring newly introduced resistance patterns combined with our accumulative knowledge 
from the previous resistance episodes. For example, by following the evolution of resistance 
pattern against colistin which emerged recently. Studies on colistin resistant Acinetobacter 
baumannii strains due to loss of lipooligosaccaharide (LOS), showed reduced growth rate 
and virulence, aligned with the first stage in the model64. Additionally, another study showed 
that overall fitness in LOS-deficient A. baumannii could be restored by eliminating two genes 
only. Both genes are involved in repairing or building the lost LOS which aligns with the 
second compensation stage65. Additionally, colistin and LL-37 have similar binding 
mechanism so cross-resistance might occur66. Thus, LOS-deficient A. baumannii might gain 
the advantage of escaping the killing by immune system free of cost67. Combining these 
features would produce a superbug or Hi-RC. Worth noting, the discovery of the mobile 
colistin resistance (mcr) gene in a plasmid is a major concern but could be still at the initial 
or the survival stage. This is evident by the low MIC-values in strains with mcr compared 
with those due to chromosomal mutations68. Another striking observation about mcr, despite 
it was identified in both E. coli and K. pneumoniae at the same time, there are more reports 
of mcr in E. coli than in K. pneumoniae27. One might speculate if this could be because E. 
coli is more capable of adapting and lower the fitness cost.  
1.4 Enterobacterales  
Enterobacterales is a heterogeneous group of Gram-negative bacteria widely distributed in 
nature. Many of them inhabit the gut of living organisms including humans as part of their 
normal microbiota. They are rod-shaped, non-sporulated, facultative anaerobes, oxidase 
negative and catalase positive. They reduce nitrate to nitrite and ferment glucose. Moreover, 
they can be motile via flagella or non-motile69. Within the context of carbapenem-resistant 
Enterobacterales (CRE), two species are particularly clinically important; E. coli and K. 
pneumoniae. Infections caused by E. coli are mainly linked to community while those caused 
by K. pneumoniae are nosocomial infections. Generally, pathogenic E. coli follows the 
“offense model” by attacking to invade making the most out of its virulence factors from the 
beginning, whereas K. pneumoniae follows a “defense model” by colonizing and only 
invading at a calculated time70.   
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 E. coli : An old yet turbulent friend  
 
E. coli is one of the most studied organisms worldwide. It inhabits the intestine of healthy 
human as a commensal strain. However, when E. coli affects extra intestinal organs such as 
the urinary tract or blood it can cause serious health issues, particularly when accompanied 
by virulence and resistance attributes. There are multiple typing approaches for E. coli. The 
one based on phylogeny divides them into A-F groups, while clinically they could be divided 
into three subsets: commensal, diarrhoeagenic known as adherent and invasive E. coli (AIEC) 
as well as extraintestinal pathogenic E. coli (ExPEC). ExPEC strains belong mainly to B2 
and D phylogroups. While commensal strains commonly belong to A, B1, C strains71. 
Treatment of ExPEC and AIEC is increasingly challenging due to the presence of resistance 
genes against third-generation cephalosporin and carbapenem in strains described as high-
risk clones (HiRCs) such as ST131.  
  K. pneumoniae: An opportunist new foe  
K. pneumoniae (KP) resides in the environment such as soil and surface water as well as on 
medical devices. In human, KP colonizes mucosal surfaces such as the intestinal and 
respiratory tracts where the effects of its colonization are mild yet known to cause 
opportunistic infections in immunocompromised individuals. Recently, KP gained an 
advantage by combining virulent and resistant attributes in the absence of treatment options 
to turn into a resilient pathogen. Thus, KP infections were seen in individuals with competent 
immune system due to resistance attributes. Also, reports of hypervirulent (HV) strains are 
increasing and such strains feature virulence factors such as siderophores72. Particular clones 
are capable to spread globally such as ST258 which is linked almost to a specific type of 
carbapenemases known as KPC.  
 Carbapenem resistant Enterobacterales 
Carbapenems are member of the β-lactam antibiotics. They are used to treat infections caused 
by bacteria resistance to other members of β-lactams including third-generation 
cephalosporins and monobactams. This is due to their broad spectrum of activity and stability 
against hydrolysis by AmpC β-lactamases and ESBLs73. The high demand of carbapenems 
in clinical settings, raises carbapenem resistance in Gram-negative bacteria including 
Enterobacterales. Carbapenem-resistant Enterobacterales (CRE) arise by two mechanisms; 
the main one is the production of carbapenemases (CP-CRE), while the second one is the 
reduction of carbapenem uptake by porin deficiency (non-CP-CPR) particularly when 
accompanied with another β-lactamases such as ESBLs or AmpCs74. Hence the terminology 
CR and CP is not interchangeable. CRE is a more general term commonly used to describe 
phenotype when the molecular mechanism is not yet known. Carbapenemases belong to three 






Figure 7. Different mechanisms of carbapenem resistance in Enterobacterales. Mechanisms of resistance 
in carbapenem resistant Enterobacteriaceae (CRE) could be divided into two categories. Those producing 
carbapenemase enzymes (CP-CRE) and those do not (Non-CP-CRE). CP-CRE could be further divided into 3 
classes based on Ambler classification. Ambler class A (Light grey) such as Klebsiella pneumoniae 
carbapenemase (KPC), Imipenemase/non-metallo-β-carbapenemase (IMI), Guiana extended-spectrum β-
lactamase (GES) and Serratia marcescens enzyme (SME). The second class is Ambler class B (dark grey), also 
known as metallo-β-lactamase (MBL). Examples of this class are New-Delhi metallo-β-lactamase (NDM), 
Verona integron-borne metallo-β-lactamase (VIM), Imipenemase/metallo-β-carbapenemase (IMP), Sao Paulo 
metallo-β-lactamase (SMP), German imipenemase (GIM) and Seoul imipenemase (SIM). The third class is 
Ambler class D (black), collectively grouped under OXA-48-like family with different variants of oxacillinase 
(OXA). Despite the second category (Non-CP-CRE) do not produce carbapenemases, they produce other type 
of β-lactamases such as Type C ampicillinase (AmpC) or Extended-spectrum β-lactamases (ESBLs) which are 
accompanied by alteration in porins or efflux pumps. Adapted from Beatriz and Perez-Gracia74. Copyright 
(2019) via CC BY license, MDPI. 
 
Class A carbapenemases are capable to hydrolyse a broad variety of β-lactams including 
monobactams, whereas class B carbapenemases lack the ability to hydrolyse monobactams. 
Historically class D carbapenemases have been mostly found in Acinetobacter spp. However, 
the OXA-48 group is mainly found in Enterobacterales75. In the following text, one member 
from each class will be discussed. 
1.4.3.1 K. pneumoniae carbapenemases (KPC) 
K. pneumoniae carbapenemases (KPC) belongs to class A. It was originally isolated from K. 
pneumoniae but later was found in other Enterobacterales including E. coli. Still KPCs are 
commonly isolated from nosocomial infections caused by K. pneumoniae compared to other 
Enterobacterales. Interestingly, KPCs are closely associated with specific clone in K. 
pneumoniae known as ST25876. Consequently, outbreaks of K. pneumoniae with KPCs are 























Arabian Peninsula or Indian subcontinent for example. Despite the sporadic reported cases 
from these regions, no outbreaks have been yet reported77-79. 
1.4.3.2 New-Delhi metallo-β-lactamases (NDM) 
Class B is unique from other classes by having a metal ion rather than a serine in the active 
site of the enzyme. The most clinically important member in this class is New-Delhi metallo- 
β-lactamases (NDM). It is strongly linked to India and the surrounding south Asian countries 
(Pakistan, Bangladesh). Yet, several NDM-1 producers have been isolated from patients with 
connection to the Balkan states or the Middle East, suggesting that those areas might be a 
secondary reservoir of NDM79,80. The spread of NDM-1 to the Middle East may be explained 
by the close social relation and population interaction with the Indian subcontinent for 
example trade and medical tourism75.   
Unlike KPC, NDM is not linked to certain clones or plasmids. This might explain the global 
wide spread of this enzyme. Additionally, the wide diversity in plasmids carrying blaNDM 
enables bacteria to carry a high number of resistance genes associated with other 
carbapenemase genes (blaOXA, blaVIM), ampC, aminoglycoside resistance genes (16 rRNA 
methylases), macrolide resistance genes (esterase), rifampicin modifying enzymes, and 
sulphamethoxazole resistance genes. Therefore, many NDM producers remain susceptible 
only to limited treatment options such as tigecycline and colistin81. In addition, genetic 
analysis of the surroundings of the blaNDM gene showed an association with bleMBL, that 
encodes bleomycin resistance protein. This coexistence has been suggested to stabilise the 
blaNDM gene75,82.  
1.4.3.3 OXA-48-like carbapenemase (OXA-48-like) 
OXA-48-like carbapenemases belong to class D. They are mainly found in north African 
countries, the Middle East, Turkey and India which are considered as reservoirs for OXA-48 
producers82. There are many variants of OXA-48-like carbapenemases including OXA-48, 
OXA-181, OXA-232, OXA-244 and OXA-163 of which OXA-48 is more common83. The 
variants differ by a few amino acid substitutions or deletions. For example, OXA-181 differs 
from OXA-48 by four amino acids.  
Generally, most OXA-48-like carbapenemases hydrolyse penicillin at a high level and 
carbapenems at a low level, leaving extended spectrum cephalosporin unaffected. Moreover, 
these enzymes are not inhibited by β-lactamase inhibitors84. It is worth noting that, OXA-163 
is distinct from other variants by hydrolysing extended-spectrum cephalosporins at a high 
level and being susceptible to β-lactamase inhibitors, while it very weakly hydrolyses 
carbapenems75. In this aspect, OXA-163 behaves like an ESBL-producer rather than OXA-
48-like enzyme, despite it differs from OXA-48 only by a single amino acid variant and a 4-
amino-acid deletion85.  
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Because of their low level of hydrolysis, OXA-48-like enzymes are the most difficult 
carbapenemases to identify84. So, their true prevalence is most likely underestimated and the 
attributed mortality rate from infections with OXA-48 producers is unknown82. Importantly, 
OXA-48 producers usually show higher level of resistance to carbapenems when associated 
with permeability defects and ESBLs75.  
In contrast to the widespread presence of blaOXA gene in Acinetobacter spp. on many different 
plasmids, the blaOXA-48 gene has only been carried in a single plasmid type with the IncL/M 
replicon, which is called pOXA-48. It has broad host range among Enterobacterales and 
between species83. This leads to a remarkable note as the current spread of OXA-48-like is 
attributed to the spread of only a single plasmid84. 
  Polymyxin Resistant Enterobacterales 
Polymyxins consist of different compounds classified from A to E. Polymyxin B and 
Polymyxins E (colistin) have gained attention recently as a treatment choice for infections 
caused by CRE. Despite the fact that they differ by a single amino acid in their structures, 
they have different pharmacological properties86. In Europe and Australia, colistin is used 
rather than polymyxin B, while in the US both are available.  Also, they have a  different 
form of activity86. While Polymyxin B is administered directly as an active antibiotic, colistin 
is administered as an inactive prodrug known as colistin methanesulfonate or colistinmethate 
sodium (CMS). CMS is an inactive drug and less toxic than colistin sulfate. After 
administration, it is converted to the active form86. Hence, CMS should not be used for 
diagnostic purposes in lab as an in vivo activation is unachievable in such conditions. Despite 
the differences between polymyxin B and E in vivo, both show similar activity in vitro as 
well as similar mechanisms of action and resistance. 
Resistance to polymyxin has evolved by genetic alteration for the targeted molecule which 
is lipid A. Lowering the net negative charge reduces polymyxin affinity. This is achieved 
with genetic alteration that involves two-component systems PhoPQ and PmrAB and their 
accompanied regulators. Polymyxins are used at varying extents in clinical settings, but 
commonly used in farming in some countries which might be responsible for the current 
increase in resistance. It is worth noting that resistance is more common in E. coli than in K. 
pneumoniae. This could be because E. coli is more associated with zoonotic spread or could 
be due to other not yet known factors such as cost of fitness. Also, the transfer of resistance 
genes is mainly vertical, except for mcr. As such we would expect a slow spreading rate. 
However, the resistance mechanism does not seem to be unique to colistin as the two-
component systems are actively used by bacteria in respond to variable external stimuli such 
as osmotic shock and low acidity. This implies bacteria are familiar to such stimuli and might 
already be adapted to compensate the cost of fitness.  
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1.5 Epidemiology of antimicrobial resistance 
The current unusual situation we are facing with COVID-19, draws the attention to the 
importance of epidemiological studies as a tool to estimate the burden of diseases and update 
the taken measures to limit the spread accordingly. The following discussion will be about 
the epidemiology of resistance against carbapenem and colistin in K. pneumoniae and E. coli. 
1.5.1 Carbapenem and colistin resistance globally 
While Europe and the US have established monitoring programs for surveillance of antibiotic 
resistance, the rest of the world is still behind. The Global Antimicrobial Resistance 
Surveillance System (GLASS) was launched in 2015 by the WHO to fill this gap and bridge 
available data. More countries enrolled in the program since the initial kick-off. Yet, we still 
lack data from countries that are not enrolled and rely on published reports to map CRE 
globally. 
The general view of carbapenemases from published papers show that KPCs are mainly 
reported from China, the United States, Italy and South America whereas NDMs are mainly 
reported from Pakistan, India, Bangladesh, the Middle East and China. IMPs are mostly 
prevalent in Japan, Taiwan and China, while VIMs are most commonly encountered in 
Greece. OXA-48 is prevalent in Turkey and Morocco76.   
On the other side, European countries reported various carbapenemase outbreaks which 
could be tracked with high resolution due to having active infection control programs. 
According to the European Surveillance Atlas of Infectious Diseases, the national trends for 
carbapenem resistance in KP increased significantly between 2015-2019 in Slovakia (from 
0.9% to 4.6%), Croatia (2.4% to 12%), Bulgaria (3.2% to 27%), Malta (4.5% to 7.8%), 
Romania (24.7% to 32.3%) Poland (0.5% to 7.7%), Spain (2.2% to 4.4%) and Portugal (3.4 
% to 10.9%) whereas a slight decreasing trend was seen in Italy (33.5% to 28.5%) and Greece 
(61.9% to 58.3%). As expected, resistance to carbapenems was much less common in E. coli 
compared to KP from the same period (2015-2019). The prevalence remained in most 
countries < 1%. Despite the slight reduction seen in Romania (1.9% to 0.6%) and Greece 
(1.2% to 1%), which is unlikely to be significant. Likewise, the slight increase in Italy (0.2% 
to 0.4%) and Spain (0.0% to 1.6%) is most likely insignificant87. There were no data 
regarding colistin resistance in Surveillance Atlas of Infectious Diseases. However, data 
about antibiotic consumption showed that Greece followed by Italy had the highest 
consumption of polymyxins between 2005 and 2019. In 2017, the consumption was reduced 
in Italy, but continued to rise sharply in Greece88. Also, published data showed that 43% of 
K. pneumoniae producing carbapenemases (KP-CP) isolates from Italy were resistant to 
colistin between 2013–201489. In Greece, colistin resistance in KP-CP increased from 0% in 
2002 to 26.9% in 201690.  
The European Centre for Disease Prevention and Control reported three outbreaks of 
carbapenem resistance in 201991. One of them occurred in north-east Germany and involved 
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17 patients from different hospitals. It was caused by KP-ST307 producing both NDM and 
OXA-48 enzymes. The clone was phenotypically resistant to colistin, but no mcr gene was 
detected, suggesting a chromosomal mechanism of resistance92. The second outbreak 
involved 223 isolates in Lithuania, of which 89% were KP and 9% were E. coli. Within the 
KP isolates there was a clonal expansion of KP-ST392 that carried blaKPC-2 gene in plasmid. 
The same plasmid was seen in the rest of the KP strains as well as in E. coli (n=21). This 
probably suggests plasmid-mediated spread of CRE in addition to clonal expansion of one 
single clone (KP-ST392)93. The third outbreak was caused by E. coli-ST38 producing OXA-
244 in different European countries including the UK. The strain has been circulating since 
2013 with 116 cases in 201993.  
Data from the U.S. CDC’s 2019 Antibiotic Resistance Threats Report showed that estimated 
cases of CRE did not increase between 2016 and 2017 as 13,100 cases within hospitalised 
patients in both years. This is quite good news that reflects the collective efforts to reach this 
goal21. No data regarding specific species were available.   
Data from the Arab League showed a predominance of OXA-48 (32.5%) and NDM-1 
(46.5%) enzymes in most countries of the region. The prevalence of CRE was ≤ 5% in Saudi 
Arabia, Lebanon, Morocco, Libya, Tunisia and Mauritania whereas the highest prevalence 
was seen in Egypt with 40% for CRKP. In the Eastern Mediterranean region, the most 
commonly produced carbapenemases were NDM-1, OXA-48-like (32.5%) or both (8.9%). 
KPC enzyme was not notable except in Egypt with only a single report from Jordan and Saudi 
Arabia. Regarding mobile colistin resistance gene, mcr-1 was detected in four E. coli strains 
from Saudi Arabia (n=1), Bahrain (n=2), UAE (n=1)77,78. 
1.5.2 Carbapenem and colistin resistance in Oman  
Over the past decade, carbapenem resistance in Oman echoes the global situation. It was not 
common before 2005. All ESBL-producers isolated between 2004 and 2005 from an 
educational hospital in Muscat (the capital of Oman) were found to be susceptible to 
carbapenems94. When blood culture isolates from a regional hospital between 2004 and 2007 
were tested using disk diffusion method,  it was found that K. pneumoniae (n=4/28), 
Enterobacter spp. (n=2/7) and E. coli (n=6/35) isolates were resistant to imipenem95. 
However, no molecular characterization was performed then.  
The NDM-1 gene was first detected in two clinical isolates of K. pneumoniae recovered from 
two patients admitted at a hospital in Muscat in 2010. The first patient was Omani yet had 
received medical treatment for pneumonia in India in 2009, while the second patient had no 
travel history, this patient was admitted in the same ward after the discharge of the first 
patient95. This was the first description of NDM-1 producers in the Arabian Peninsula and in 
the Middle East. During the period between 2010 and 2011, carbapenem-resistant K. 
pneumoniae, E. coli and E. cloacae were identified from three different hospitals. The 
carbapenemases in these isolates were identified as blaNDM-1 (n=11/22), blaOXA-48 (n=5/22 ) 
and one isolate had both blaOXA-181 and blaNDM-196. Additionally, a study aimed to identify 
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carbapenemase-producers among clinical isolates at educational hospital in Oman (SQUH) 
during the period between January 2010 and April 2011 found most of the isolates to be non-
MBL producers, though three strains produced NDM-197. Regarding colistin resistance, 
Sonnevend et al. reported four E. coli strains harboring mcr-1 gene from three neighbouring 
countries to Oman; the United Arab Emirates (UAE), Saudi Arabia and Bahrain in 201698. 
In 2017, Mohsin et al. reported the first mcr-1 from E. coli isolates in Oman99. In summary, 
carbapenemases were not common in Oman before 2013, though sporadic cases were 
reported, no national surveillance with large study samples from different hospitals took 
place.  
1.6 Typing bacterial strains 
Tracing back the source of resistant strains helps in controlling the spread and minimising 
the impact of the problem. Also, it is a tool to evaluate the epidemiological impact of 
successful clones that require more attention to control. As such the emergence of new high-
risk clones will be followed and the evolutionary process will reveal much more about the 
dynamics and spread of such clones. This will eventually help to narrow down the knowledge 
gap remains in the field.  
There are many approaches for typing bacteria, which depends mainly on bacterial genetic 
characteristics. For example, capsule typing is more common in KP than in E. coli compared 
to O-serotyping since the variation of capsules is more profound in KP. With current 
advancement in sequencing approaches, there is a move towards whole genome sequencing 
(WGS) which opens the door for a wide range of ways to performing in silico typing 
including CRISPR and phages. Here, I discuss CRISPR system as a typing tool in E. coli.  
1.6.1 CRISPR-Cas system 
In 1987, Ishino et al. detected a repetitive stretch of DNA in the chromosome of E. coli K-
12, downstream of the alkaline phosphatase isozyme iap gene100. Similar findings were 
reported from other bacterial species. A distinct feature of these elements was that the repeats 
were interspaced by noncoding, non-repetitive sequences of similar length now known as 
spacers. Mojica et al. defined these repetitive elements as short regulatory spaced repeats 
(SRSR) in 2000101. In 2002 Jansen et al. proposed the name cluster regularly interspaced 
short palindromic repeats (CRISPR)102. Additionally, they observed that these repetitive loci 
were always accompanied by conserved sets of genes encoding nucleic acid processing 
enzymes named CRISPR-associated genes (Cas). In 2005 three groups independently 
observed that some of the interspaced sequences were 100% identical to DNA sequences 
from viruses and plasmids which was a major breakthrough103-105. Eventually CRISPR-Cas 
was considered as an adaptive immune system that protects bacteria from getting invaded by 
bacteriophages or plasmids carrying similar sequences. 
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1.6.1.1 Components of CRISPR-Cas system 
Generally, the CRISPR-Cas system consists of CRISPR loci and cas genes. Each CRISPR 
locus, also known as CRISPR arrays, motifs or cassettes, have three components; spacers, 
direct repeats (DR) and a leader (L) (Figure 8). The spacers are greatly variable in their 
sequences that match part of the DNA sequences in plasmids and phages. The matching 
sequences in phages or plasmids are called protospacers and assumed to be the origin of the 
spacers104.  
On the contrary, DR sequences are greatly conserved with the possibility of few modified 
nucleotides sequences101. Kunin et al. classified DR in CRISPR systems for multiple 
organisms into 12 clusters of which two of them (DR-2 and DR-4) were recognised in E. 
coli106. Additionally, each CRISPR locus has one leader, where a leader is an AT-rich 
sequence with promoters that direct transcription of the adjoining locus.  
 
 
Figure 8. Structure and function of CRISPR-Cas system in E. coli as a typing tool. Each CRISPR locus 
consists of constant repeated sequences called direct repeats (DR; black diamond) and unique sequences 
embedded between them called spacers (coloured rectangular). In E. coli, there are two subtypes of CRISPR-
Cas system; I-E and I-F1. A| I-E subtype has 2 main CRISPR loci (CRISPR 2.3 and CRISPR 2.1) and one extra 
locus occurs occasionally (CRISPR 2.2) with leaders (L) at the start of the two main loci. I-E has eight cas 
genes (white boxes). B| I-F1 subtype has two CRIPPR loci (CRISPR 4.1 and CRISPR 4.2) with a leader (L) in 
each locus and six cas genes (white boxes). C| CRISPR typing is based on extracting spacer sequence 
information. Unique spacers are represeted with different colored rectangles. An allele is define as a unique 
combination of spacers in the four CRISPR loci as shown in the table. Adapted with permission from Sharat 







Regarding cas genes, there are 8 in I-E subtype(cas3, cas8e/cse1, cas11/cse2, cas7/cse4, 
cas5, cas6/cse3, cas1, cas2) and six in I-F1 subtype (cas1, cas2-cas3, cas8f1/csy1, 
cas5f1/csy2, cas7f1/csy3, cas6f/csy4) as per the updated classification done in 2020108. Of 
notice, cas1 and cas2 proteins are present in all CRISPR-Cas systems that are predicted to be 
active109.  
1.6.1.2 Classification  
The CRISPR-Cas system is extremely diverse. The current classification  consists of 2 
classes, 6 types and 33 subtypes108. Each system consists of a set of cas genes along with 
CRISPR arrays. CRISPR-Cas system in E. coli belongs to class 1, type I with two subtypes, 
I-E subtype also known as Ecoli and I-F subtype also known as Ypest. The later was 
reclassified into I-F1 recently as a defective CRISPR-Cas variant since it lacks cas3 gene 
which is required for interference process. Since interference involves recognition and 
breakdown of the invaded DNA or RNA, this suggests a distinct function other than the 
adaptive immunity that is already recognised for CRISPR-Cas system108. 
I-E subtype consists of three CRISPR loci; one downstream iap gene and two between ygcE 
and ygcF genes (Figure 8). The two loci between ygcE-ygcF genes were separated by 0.5 kb 
highly conserved AT rich sequence. Usually only one CRISPR locus is observed between 
these genes. However, the extra locus following the AT rich sequence might exist 
occasionally. The less common I-F1 subtype consists of two loci between clpA and infA 
genes. E. coli CRISPR-Cas system did not gain much attention since its recognition as being 
static. Thus, not much time was invested on its nomenclature either. While PCR reactions 
can only amplify DNA sequenced tailored to the designated primers, WGS creates confusion 
regarding the classification due to the lack of a database that could specifically name the 
identified CRISPR loci. Previous studies describing E. coli CRISPR-Cas system, used three 
different nomenclatures; Touchon et al., Villasenor et al. and Yin et al.110-112(Table1). Since 
Diez-Villasenor et al. classification integrated the type of direct repeat in their nomenclature, 
here we use their scheme with minor modifications. To keep it simple, we only state the name 
of the observed arrays and ignore the label indicating the absence of arrays e.g. CRISPR 2.2-
3 and CRISPR 4.1-2 (Table 1). 
 
Table 1. Nomenclature of the CRISPR-cas system in E. coli110-112   
  Classification  Touchon et al. Diez-Villasenor et al. Yin et al. 
I-E  cysH-(cas genes)-CRISPR-iap CRISPR 1 CRISPR 2.1 CRISPR 1 
 ygcF-CRISPR-(0.5 kb AT rich)-CRISPR-ygcE CRISPR 2-ND* CRISPR 2.3-CRISPR 2.2 CRISPR-2a-CRISPR 2b 
 ygcF-CRISPR-(0.5 kb AT rich)-ygcE CRISPR 2 CRISPR 2.3-2 CRISPR 2a 
I-F1  clpA-CRISPR-(cas genes)-CRISPR-infA CRISPR 3-CRISPR 4 CRISPR 4.1-CRISPR 4.2 CRISPR 3-CRISPR 4 
  clpA-CRISPR-(cas genes)-infA CRISPR 3 CRISPR 4.1-2 CRISPR 3 




It is widely accepted that the CRISPR-Cas system plays a role as an active adaptive immune 
system for bacteria, where a piece of DNA (protospacers) from previous invaders either 
bacteriophage or plasmid are incorporated within the CRISPR-Cas system in the bacterial 
genome as spacers. If a bacterium is attacked with a similar bacteriophage or plasmid again, 
the presence of an active CRISPR system will cleave the foreign DNA. This mechanism 
consists of three stages, adaptation, expression and interference109. However, it is beyond the 
scope of this thesis as we are more interested in CRISPR as a typing tool and looking for 
association between CRISPR and bacterial contents of phages and plasmids. 
The CRISPR-Cas system was found to be a useful tool for typing bacterial diversity. The 
resolution of the subtyping depends largely on the spacer’s content yielding a higher 
resolution in strains with diverse spacers. Thus, active CRISPR loci could be a useful tool to 
trace outbreaks. Such typing system has been used in spoligotyping M. tuberculosis and C. 
diphtheriae113. In E. coli, polymorphisms in CRISPRs of enterohemorrhagic E. coli (EHEC) 
were found to provide a higher resolution typing profile than the established techniques based 
on stx and eae polymorphism alone or in combination with O:H serotypes114. Likely, Jiang 
et al. studied shiga toxin-producing E. coli (STEC) from various sources. They found a 
similarity in spacers content and order in strains with identical serogroups115. Additionally, 
Yin et al. found that STEC isolates with same H type would carry same or similar spacers112. 
Also, the virulent strain of B2-phylogroup is known to lack CRISPR-Cas system110. 
Regarding commensal strains, it is questionable if CRISPR is a useful tool for typing or if it 
plays a role as an active immune system since it was considered static116. Also, Mojica et al. 
suggested that the pathogenicity of prokaryotic population depends largely on bacteriophages 
and plasmids contents117. Thus, targeting these mobile elements by CRISPR might affect 
bacterial pathogenicity and open the door for a new treatment approach. 
On the other side, the correlation between antibiotic resistance and CRISPR-Cas system is 
not yet conclusive. Studies published on Enterococcus faecium published studies showed that 
absence of CRISPR-Cas system could distinguish antibiotic resistant species with a wide 
variety of plasmids harbouring resistance genes from susceptible strains. For example, 
Palmer and Gilmore reported an inverse correlation between CRISPR-Cas and antibiotic 
resistance118. A similar finding was reported by Tremblay et al. as they observed a total 
absence of CRISPR in seven ampicillin-resistant E. faecium isolates119. Likewise, Van 
Schaik et al. studied 10 E. faecium isolates from different sources (canine and human) and 
concluded there was an association between increased antibiotic resistance and the absence 
of CRISPR-Cas system120. However, no such correlation was seen in E. coli. A study 
conducted on E. coli strains (n=263) obtained from different sources (humans and animals) 
with various level of plasmid-encoding antibiotic resistance genes reported no association 
between the acquisition of plasmids with the presence or activity of CRISPR system121. 
Likewise, Dang et al. compared CRISPR-Cas system in a collection of fecal commensal and 
uropathogenic E. coli (n=162). They did not  observe consistent correlation between 
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CRISPRs and resistance genes yet they observed a correlation between CRISPR activity and 
pathogenicity between both groups122.  
All in all, active CRISPR-Cas system in E. coli is lost to gain virulence factors usually 
through gaining prophages (transduction). As such CRISPR analysis might help to 
distinguish pathogenic from commensal E. coli strains. However, the gain of  resistance genes 
in E. coli  which usually transmitted by plasmids (conjugation) does not correlate with 
CRISPR activity. Such findings suggest CRISPR-Cas in E. coli could be particularly active 
against phages but not plasmids or perhaps plasmids more frequently utilise anti-CRISPR to 
escape being recognised by CRISPR-Cas system123. However, such selective activity of 
CRISPR or anti-CRISPR between plasmids and bacteriophages is lost not clear124. In short, 
E. coli has a distinct CRISPR-Cas system from other microbes where its evolution appears 
more complex than simple spacer acquisition and its function might be other than immunity 
system. Many gaps yet remain to be filled in this respect.  
1.7 The light at the end of the tunnel 
Despite the challenges we face due to antibiotic resistance, we as humans did impressive and 
work in our collective efforts to make the best out of the current situation and move forwards. 
We looked outside the antibiotic box for innovative approaches to clear infections. For 
example, studying ways to optimise or enhance the activity of our own immune system via 
the intake of vitamin D supplement125. Also, developing therapies derived from antimicrobial 
peptides to treat infections is another approach126-130.Replacing the notorious drug resistant 
strains colonising the gut with healthy microbial community by faecal transplant or the intake 
of probiotics is intensively investigated.  Bacteriophages being the natural bacterial enemy, 
could be utilised to cure infections by making use of CRISPR as a genome editing tool. Most 
of these approaches are exciting but still under development. Therefore, improving currently 
available drugs within the antibiotic box seems more practical. 
Studies regarding combinational therapy with different classes of antibiotics are actively 
reported131,132. Additionally, a new generation of β-lactamase inhibitors has been introduced 
to the market recently including imipenem-relebactam (Recarbrio) in 2019133. In 2020 
cefiderocol was approved for treatment of infections caused by Gram-negative bacteria. It 
belongs to the cephalosporin family and has a unique entry into the bacterial cell via the iron-
transport system. It shows a high spectrum of activity and stability against all β-lactamases 
including carbapenemases which makes it very interesting as a treatment option when the 
mechanism of resistance is not yet known133,134. 
However, recycling the available drugs by chemical modifications to manoeuvre around 
resistance mechanisms is not as efficient as introducing new classes of drugs. Historically, 
resistance to such modifications has developed rapidly. Therefore, development of 
completely novel antibiotics is a desirable goal. Malacidin and teixobactin are examples of 
such novel drugs. although they only have activity against Gram-positive bacteria135,136. What 
is quite interesting about these drugs is the claim that bacteria cannot resist them. The 
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discovery of drugs with high potential of no resistance would be a game changer that raise 
our hope for a better future.  
 
 
Figure 9: Chemical modification of available β-lactam drugs as a treatment option. The chart represents 
(green) some of the remarkable recycled β-lactam drugs which were approved by FDA (food and drug 
adminstration). One combination therapy was used clinically as no other option to treat the patient was available 
(yellow). Three drugs are under clinical trials with promising high spectrum of activities (pink). ? ; indicates 
the drug shows variable effect on AmpC. *; varborbactam and relebactam do not inhibit OXA-48-like enzymes. 
When they are accompnied with meropenem and imipenem, the comination drugs are ferquently active against 
OXA-48-like family because of the carbapenem component rather than the inhibitory effect. Adapted with 





























AIMS OF THE THESIS 
 
The thesis is based on three hypotheses (Figure 10) to investigate the following three main 
aims 
I. To investigate the magnitude of the antibiotic resistance in clinical Enterobacterales 
isolates from Oman. Particularly carbapenem-non-susceptible  E. coli (Paper I) and 
K. pneumoniae (Paper II) as well as colistin resistance (Paper III). This aim is 
achieved by conducting surveillance studies. Additionally, we aim to uncover the 
population structure of resistant strains and investigate if they are correlated to the 
already known international resistant clones.  
 
II. To study the ability of multidrug resistant strains particularly colistin resistant 
isolates to esacpe innate immune effectors including LL-37 and to examine the 
putative cross- resistance between colistin and LL-37 ( paper III and paper IV).  
 
III. To look into potenential solution to treat infections caused by resistant strains with 
the current available antibiotics in the market. This is achieved by looking for 
synergistic effect with antibiotics that already available in the market (paper III and 
paper V).  
 
 
Figure 10. Hypotheses used to address the aims from the research. We aimed to test three hypotheses. First, 
we hypothesize the resistant strains from Oman belong to some of the major known international clones (Papers 
I-III). Second, we hypothesize phenotypical resistance comes with a fitness cost. Also, we assume there is cross-
resistance between colistin and LL-37 (Paper III-IV). Finally, we hypothesize that combination therapy is an 







In this chapter I will discuss the methodology we used to test the hypotheses framed to 
achieve the aims. The methodologies we used can be classified into wet or dry lab works. 
The clinical isolates were obtained from different hospitals in Oman based on one criterion: 
reduced susceptibility to carbapenem. Such isolates routinely referred to the public health 
laboratories for further characterization. We used a collection of isolates obtained in 2015 for 
this study.  
3.1 Ethical consideration 
Ethical approval for the study was obtained from Ministry of Health in Oman 
(MD/R&S/32/2015). The approval includes collecting anonymized clinical data, shipping the 
isolates to Sweden and to carry the research and analysis on them. The isolates were used in 
all five papers.  
Additionally, two ethical permits were granted to carry experiments in paper IV. For the 
collection of blood samples from healthy volunteers we used initially the permit (dnr 2000-
360/00) which was approved by the Regional Ethical Review Board in Stockholm and 
updated in 2019 by the same committee (dnr 2019-02519). The permit (dnr 19204-2017) to 
carry zebrafish experiments was approved by the Ethical Review Board, Stockholm, animal 
research Committee and the Swedish Board of Agriculture.   
3.2 Dry lab work 
Since most of the analyses were based on data obtained from whole genome sequencing 
(WGS), the dry lab work constitutes the majority of the work in the study in all papers but to 
a lower extent in paper IV. The phenotypic test and identification were re-examined at 
Karolinska Institute. Samples of interest based on their resistance patterns were selected for 
WGS.  
In total there were 35 E. coli isolates. All of them were included in Paper I yet 20 isolates 
were utilized in Paper V. Regarding K. pneumoniae, there were 237 isolates. All were 
included in Paper II. Out of them 25 were colistin resistant isolates which were studied further 
in-depth in Paper III. In Paper IV, we studied seventeen K. pneumoniae isolates of which  
eight were colistin resistant whereas nine were colistin susceptible as a control group. We 
followed similar protocol for both species as outlined in the flow chart (Fig 11). In summary, 
DNA was extracted and quantified prior to sending the sample for Illumina short read 




Figure 11. Summary of the workflow related to the analysis based on whole genome sequence. We started 
the workflow by species identification using MALDI-TOF (matrix assisted laser desorption ionization-time of 
flight) mass spectrometry followed by confirmation of carbapenem non-sucebtibility prior to sending the strains 
for short read sequencing. We utalised available analyses tools to screen for virulence and resistance genes. As 
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1. Around 300 Klebsiella pneumoniae and E. coli clinical 
isolates from 12 hospitals in Oman were studied.
2. Species confirmation was performed 
using MALDI-TOF.
3. We performed phenotypic antimicrobial senstivity tests including 
disk diffusion, gradient strips (E-test), broth microdilusion and Carba 
NP.
5. Reads were assembled using Unicycler or Spades. Several online databases were 
used for genomic analyses including, MicroSalt, BIGsBD, Kaptive, Kleborate, CARD, 
CGE, PHASTER, CRISPRcasFINDER and EnteroBase. Also, CLC software was used to 
screen mutations in genes regulating efflux pumps and porins 
 6. Snippy was used for SNP-calling after  excluding recombination events with 
Gubbins. A phylogentic tree was infered using FastTree. Graphic design was 
done using R with addition of packages: tidyverse, tidytree, Biostrings, cluster 
and ggpubr and grid.
4. DNA was extracted for carbapenem non-susceptible 
 isolates. Then, quantified with Qubit prior to be sent to an  
external facility (SciLife) for sequencing with Illumina-NGS.  
For selected strains we performed long read sequencing  




the quality of the reads using FASTQC. The reads which passed the quality check were 
analysed further whereas the reads with low quality were re-sequenced. Regarding E. coli 
strains, reads with accepted quality were used to screen for mutations in genes codify AcrAB-
TolC efflux pump and porins or their regulators by CLC program. The generated data were 
presented in Paper I and Paper V. Furthermore, reads were uploaded in EnteroBase pipeline. 
The assembled files were downloaded from the database and the gaps were closed by aligning 
the assembled files back to the original reads via Pilon software. Then, the polished fasta files 
were uploaded to Center of Genomic Epidemiology, CRISPRcasFINDER and PHASTER 
databases to screen for resistance, virulence, CRISPR and phage contents. Additionally, 
phylogenetic trees were constructed in a similar manner to K. pneumoniae as described 
below.  
Regarding K. pneumoniae, the strains were assembled by Unicycler then the FASTA files 
were uploaded into BIGSdb to assign new STs. CARD and Kleborate databases were used 
to screen for resistance and virulence genes, respectively. To understand the population 
structure, we placed the bacterial genetic background in a phylogenetic tree. This has been 
achieved by calling the SNPs with Snippy, filtering putative recombination events by 
Gubbins, reducing the filtered alignment to the core polymorphic sites by SNP-site, building 
a matrix by SNP-dists and eventually randomized accelerated maximum likelihood 
(RAxML) tree by RAxML program. K. pneumoniae strains used for paper III, were analysed 
in a similar manner except for phylogenetic tree in which CLC program was used to build a 
neighbour-joining tree for some strains. Additionally, Sanger sequence or long read sequence 
with MinION sequencer were performed for selected isolates to increase the genetic 
resolution obtained by Illumina short read sequencer.  
We encountered some challenges in the genomic analyses. These challenges were not unique 
by any means as they are usually encountered in many labs due to limitation of the available 
analysis’s tools. For example, after filtering recombination sites we noticed unexpected 
outcome in which isolates with similar classical ST types had high SNP-differences. The 
recombination events are identified as sites with elevated densities of base substitutions. The 
drawback with this approach, it cannot distinguish sites with high heterogenicity from those 
encountered recombination events137-139. To overcome this, we masked STs genes prior to 
filtering out recombination sites. We acknowledge this is not the best approach but the one 
we could implement with the current tools at hand.   
 3.3  Wet lab work 
Data in Paper IV and to less extend in Paper III  involved wet lab works. Here I will discuss 




3.3.1 Choice of medium  
The choice of growth media can affect the outcome of the experiment 140. Initially we tested 
different media such as LB with or without RPMI-1640 medium. LB (Lysogeny broth or 
known to be abbreviated for Luria-Bertani) was developed by Bertani in 1951 to optimize 
plaque formation141. LB media were widely used in molecular microbiology such as plasmid 
DNA and recombination but discouraged for physiological studies for reasons discussed 
below.  
LB medium has complex sources of carbons. It consists of tryptone as a source of amino 
acids, yeast extract as a complex source of organic compounds helpful for bacterial growth 
as well as sodium chloride for osmotic balance and transport. Bacteria during the initial stage 
of exponential growth will utilize easy to digest compounds as a source of carbons yet when 
these are depleted then bacteria will switch into more complex sources which will create a 
pause in bacterial growth142. Such slow in growth might alter the size and the structure of cell 
wall hence interfere with physiological studies. Another disadvantage to utilize LB in 
physiological studies is the contents of divalent cations such as magnesium and calcium. This 
has been pointed out by a paper cited three times so far despite the importance of the message 
it carries143. Divalent cations play a role in in the stability of LPS and hence cell wall of 
Gram-negative bacteria as discussed previously (section 1.2.1.1.3). A third factor is that LB 
media are sold as premixed capsules contain variable amount of bile salt. Bile salt is toxic to 
bacterial cell which is usually expelled by activating AcrAB-TolC efflux pump144,145. 
However, once activated the pump will expel other materials along the way such as antibiotic, 
thus interfering with experiments studying bacterial susceptibility to antibiotics as the case 
in this thesis. Moreover, bacteria lacking AcrAB-TolC efflux pump will not survive as they 
will be affected with bile salt toxicity. The content of bile salt in each premixed batch of LB 
varies. We noticed this as using a fresh batch of LB might change how bacteria behave in the 
experiment. Particularly since the study of colistin resistance is sensitive to divalent 
cations and active efflux pump is known to cause resistance to colistin44. For these reasons 
we chose to shift from using LB to MHB (Mueller Hinton Broth).  
Mueller Hinton Broth was developed by Muller and Hinton to study gonococcus and 
meningococcus in 1941146. It consists of beef extract and casein hydrolysate as sources of 
amino acids and carbohydrates as well as starch which absorb toxins released by bacteria so 
they do not interfere with antibiotic activity for example. For this reason and for being 
nonselective and nondifferential medium in which most bacteria are capable to grow, MHB 
is recommended to be used for antibiotic susceptibility assays after cations adjustment. 
Initially the recommendation was to perform broth microdilution (BMD) for cationic 
antibiotics such as colistin using MHB without cations adjustment as their mechanisms of 
action relied on competing with calcium and magnesium to bind to bacterial cell wall147. 
However, the latest update recommends using the cation-adjusted media (CaMHB) which 
we used in our work here. 
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Another media we have used was RPMI 1640 developed in 1966 at Roswell Park Memorial 
Institute148. It is a growth medium for culture cells. We utilized this media with innate 
effectors such as blood. Others proposed the use of RPMI1640 with 5% LB in susceptibility 
assays will improve the estimation of antibacterial activity compared to CaMHB149. 
However, we still have concerns regarding the use of LB and a better approach could be to 
use RPMI with 5% CaMHB. Yet, we only noticed such significant difference in MIC-value 
if tested in CaMHB or RPMI with 5% LB in azithromycin. 
3.3.2  Bacterial inoculum  
Bacterial growth curve can be divided into four stages: lag, exponential, stationery and death 
phases. During the lag phase bacteria invest time to adjust to the new environment 
and prepare the precursors to grow and divide. There is no growth or duplication at this 
phase, as such the growth curve is flat. The next stage bacteria start to grow exponentially. 
This is an optimum stage to test the effect of intervention in bacteria. Since the nutrient 
supply is available, the size and the structure of bacterial cell are normal and intact. The 
changes might only be attributed to the intervention or treatment factor. This phase is 
followed by a stationary phase in which bacterial rate of growth equals the rate of death, thus 
presented with a flat line as no net growth. Here, bacteria behave differently as they compete 
for the limited remaining nutrients and their structure and size might be affected. Also, the 
medium would contain waste as a by-product of bacterial metabolism. This might be of 
interest for specific studies like how bacteria behave in starvation. Yet, for intervention 
studies it is not optimal since many factors might affect the outcome apart from 
the treatment.  Besides, the bacteria initial inoculum determines how fast bacteria could move 
from one stage to the following one. Exposing bacteria to antibiotic at the lag phase would 
have a bigger impact in the outcome compared to the exponential phase. 
We used different bacterial initial inoculum for different assays (Table 2). We based this 
on previously published reports. In LL-37-kill assay and blood-kill assay, we used similar 
initial inoculum of 5x107 cfu/ml. For zebrafish and serum assays we used 4x104 cfu/ml. In 
experiments related to electron microscopy and zeta potential we used higher inoculum of 
1x108 cfu/ml. Whilst we deliberately used low bacterial inoculum for the growth curve 
experiments (1x103 cfu/ml) to observe the initial lag phase as starting with a higher inoculum 
might mask this since bacteria replicate fast. It is worth noting, the initial inoculum might 
affect the outcome. This is one of the reasons some of our findings do not aligned with the 
published data. There is no agreement on this in the literature, but the variation is 
acknowledged to impact the outcome. This is evident by the recommendation to use 5x105 
cfu/ml as bacterial starting inoculum for antimicrobial susceptibility assay to control 
for growth variation. One issue with growth curve experiments is that it does not directly 
reflect the living bacterial cell, but rather measure the turbidity of the media as an indication 
of the growth. This could be true until the bacteria enter the stationary phase where bacteria 
start to die due to lack of nutrients. Yet still the turbidity is high since turbidity is not related 
to viability.  
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Table 2: Medium and initial bacterial inoculum used in different assays 
Experiments* Bacterial inoculum  cfu/ml (log10) 
Medium 
Time-kill assay   
      LL-37 ∼5x107 (7.5) 	 CaMHB  
      Blood ∼5x107 (7.5)  40% blood diluted in RPMI1640  
     Serum ∼5x104 (4.5) 	 20% serum diluted in PBS 
Combination assay 	  
      Paper III ∼5x107 (7.5) 5% RPMI1640 diluted in CaMHB with treatment of choice 
      Paper V ∼1x106 (6) CaMHB  
Zebrafish  ∼5x104 (4.5)  E3 medium  
Zeta potential ∼1x108 (8)  PBS or deionized water (DIW)  
Electron microscopy  ∼1x108 (8)  CaMHB  
Broth microdilution (BMD)  ∼5x105 (5.5)  CaMHB  
Growth curve measurement   ∼1x103 (3)  CaMHB  
CaMHB; cation adjusted Mullar Hinton broth, PBS; phosphate-buffered saline, RPMI1640: culture medium developed 
by Roswell Park Memorial  Institute, CFU; colony forming unit. * If otherwise not indicated, the assays listed were 
presented in Paper IV. 
 
3.3.3 Time-kill assay  
For time-kill experiments, the bacteria were grown exponentially and diluted to the desired  
concentration prior to the start of the assays (Table 2). Then incubated for two hours with the 
desired treatment e.g. serum, blood or LL-37. Followed by serial dilution and incubation in 
blood agar overnight. The next day, we counted the colony-forming unit (CFU-count). 
Regarding serum-kill assay the practice of using 20 % serum diluted in phosphate buffered 
saline (PBS) is commonly used and accepted in the literature, despite the rationale behind the 
practice is not clear. Regarding blood-kill assay we diluted blood in 40% RPMI1640. We 
optimized the dilution to get a measurable outcome within 2 hours.  
3.3.4 Zeta potential 
As per the general agreement in literature, colistin resistance arises due to reduced negative 
charge in the bacterial cell wall. We aimed to measure bacterial charge with zeta potential. 
Zeta potential will give the whole net charge, we were particularly interested in measuring 
LPS charge. Despite this, the general trend would remain the same though the 
magnitude might be affected with other factors such as the ionic content of the 
medium. Thus, we used two media, PBS and deionized water (DIW) to control 
for ions effect. Also, we used  Proteus mirabilis as a control fot machine performance since 
it is intrinsically resistant to colistin150. We studied two genetically close K. pneumoniae 
clinical strains differing in their tolerance to colistin. As a control we used the laboratory 
reference strain (ATCC25955).  
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P. mirabilis showed low negative charge compared to the rest of the strains. The data 
regarding the control showed lower negative charge compared to the colistin resistant strain. 
The finding we saw was unexpected and surprising. The resistant strains (Col-
R) showed higher negativity than the colistin susceptible (Col-S) and the reference strain 
(ATCC25955). Further work could be done to look in-depth to such striking finding. For 
example, measuring the contact angle which gives a clue about hydrophobicity of bacterial 
surface as described previously151. This could be relevant since polymyxins utilise 
electrostatic and hydrophobic interaction to bind with bacterial cell. Another approach could 
be to extract lipid A for more specific characterization of the surface charges with mass 
spectrometry as described previously152. Additionally, atomic force microscopy (ATM) 
might help in understanding how polymyxins interact with bacterial cell following similar 
methodology used for a different goal but could be implemented here153. 
Moreover, measuring zeta potential for other colistin resistant strains might give a clue if this 
is a trend in the Omani isolates or whether this particular strain is an exception. Another 
challenge with studies related to colistin resistance is the lack of an international reference 
strain. The availability of a reference strain aids in relating data from different 
labs. Currently, only clinical strains were studies. The challenge with clinical strains, their 
genetic content varies which might affect the findings.   
3.3.5  Combination assays 
We performed combination assays as presented in Paper III and Paper V. We defined the 
observed effect as synergistic (reduction of ≥ 2 log10), additive (reduction of ≥ 1 log10) or 
antagonistic (increase of  ≥ 2 log10) by comparing the combination result with the most potent 
single antibiotic as described previously154.  
In Paper III, we focused on colistin and carbapenem resistant K. pneumoniae. We used time-
kill assay to test the effect of two antibiotics in combination with polymyxin B (2 mg/L);  
rifampicin (5  mg/L) and azithromycin (0.25 mg/L). The selection of antibiotic concentrations 
was based on previously published papers. In Paper V we explored combination therapy for 
carbapenem-non-susceptible E. coli against a wide range of antibiotics with different 
concentrations; aztreonam (2, 8, 65) mg/L, meropenem (2, 16, 64) mg/L, minocycline (0.5, 
4 and 16) mg/L, polymyxin B (0.25, 0.5, 1 and 2) mg/L and rifampicin (1, 8, 32 ) mg/L.  We 
utilized screening machine based on time-lapse microscopy (oCelloScope). Images were 
taken at different time interval and bacterial growth was assessed via kinetics algorithms e.g. 
the background corrected absorption (BCA) and segmented extraction of surface area 
(SESA)155. We considered there is bacterial growth when BCA value is > 8 in combination 
with a maximum SESA of > 5.8 was noticed. One of the limitations is the inability to 
distinguish filament from single cell which result in false negative. This is particularly 
obvious in antibiotic causing filamentation such as aztreonam which was compensated by 




RESULTS AND DISCUSSION 
  
In this chapter,  I will discuss the results and the validity of the hypotheses we raised to 
achieve the aims of this work. Since the work was based on three aims. I will discuss each 
aim in a specific section.   
4.1 Population structure of resistant strains in Oman  
We studied population structure and β-lactam resistance mechanisms of E. coli strains (n=35) 
in Paper I. Similarly, we investigated the genetic background of K. pneumoniae clinical 
isolates (n=237) and their mechanisms of resistance against β-lactam (Paper II) and colistin 
(Paper III). 
4.1.1 E. coli : Paper I 
We observed high clonality reflected by diverse sequence types (ST) in E. coli strains. Within 
35 strains we found 21 unique STs, 11 distinct H-serotypes, 16 O-serotypes and 22 CRISPR-
types. Collectively, we assigned an overall allelic number for each strain by combining these 
typing schemes. At least there were 6 pairs of closely related strains (Table 3). Furthermore, 
we studied SNP-differences between strains within these 6 pairs. At least in three pairs, 
strains were close genetically with SNP-differences ≤ 2 which suggests the occurrence of 
silent transmission events.  
The presence of a diverse CRISPR-type (22 types) was relatively unexpected since the 
CRISPR-Cas system is considered to be static in strains with similar MLST types in E. coli116. 
We have seen three CRISPR-types in ST38 for example (Table 3). The diversity might 
indicate different genetic background in the studied isolates since the samples were not 
collected for an outbreak investigation but rather for national surveillance. Also, it implies 
CRISPR typing could identify outlier strains.  
Carbapenemase genes were detected in 22 strains (59%). Isolates produced either NDM 
(n=13), OXA-48-like (n=7) or both enzymes (n=2). We did not detect any KPC enzyme. This 
aligns with data published previously that consider the Middle East a reservoir for NDM and 
OXA-48-like carbapenemases79,82,156. Furthermore, three isolates were carbapenem non-
susceptible, but we could not detect genes codifying carbapenemase on them. The three 
isolates were negative by Carba-NP. As Carba-NP has limitation in sensitivity towards OXA-
48-like enzymes, one might speculate the isolates possibly could harbour a novel OXA-48-
like enzymes which could not be detected in the database116.  
As the three non-carbapenemase producing strains harbored other β-lactamases (ESBL or 
AmpC), we thought to screen if they mutated to alter cell wall permeability or activate efflux  
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Table 3: Different typing approaches used to study population structure in E. coli 
 
 





OM898 A 1702 O89 H9 1 1 
0  
 
OM852 A 1702 O89 H9 1 1  
 
OM1626 A 167 O89 H5 1 3 
1  
 
OM855 A 167 O89 H5 1 2  
 
OM1071 A 167 O89 H9 1 3   
OM979 A 617 NA H10 2 4   
 
OM5639 A 617 NA H10 3 4  
 
OM693 A 617 O89 H10 4 5   
 
OM1398 A 540 O9 H30 5 6   
 
OM211 A 361 O9 H30 6 7 
14  
 
OM112 A 361 O9 H30 6 7  
 
OM1576 A 46 O9 H10 7 8   
 
OM147 B1 101 O131 H31 8 9 
2  
 
OM79 B1 101 O131 H31 8 9  
 
OM1341 B1 156 O177 H28 9 10   
 
OM664 B1 448 O160 H8 10 11   
 
OM561 C 410 NA H9 11 ?   
 
OM1273 C 410 O8 H9 11 12  
 
OM1301 C 410 NA H9 11 ?  
 
OM853 C 652 NA H9 12 13   
 
OM1609 F 6870 O45 H6 13 14   
 
OM78 F 1340 NA H6 X 15   
 
OM260 B2 131 O25 H4 X 16   
 
OM333 B2 73 O6 H1 X 17   
 
OM1692 B2 127 O6 H31 X 18   
 
OM1136 B2 1193 O75 H5 X 19   
 
OM126 D 2914 O166 H15 14 20   
 
OM1168 D 405 O102 H6 15 21   
 
OM82 D 405 O102 H6 16 22 7  
 
OM839 D 405 O102 H6 16 22  
 





OM481 D 38 O86 H18 18 24   
 
OM1433 D 38 NA H30 19 25   
 
OM234 D 38 O7 H18 20 26 10  
 
OM347 D 38 O7 H18 20 26  
 
NA: Not determined, X: CRISPR-Cas system is absent, ?; Strains similar in known typing approaches but O-serotype since 







pumps. One strain had wild-type variants in all screened genes. However, our understanding 
of the genes involved in regulating porin and efflux pump activities is continuously evolving. 
Here we screened for mutations in ten genes (ompCFR, envZ, acrR, marABR soxSR) are 
known to regulate activities of porins and AcrAB-TolC efflux pump. We did not screen for 
acrAB, tolC and ramA genes known also to affect AcrAB-TolC efflux pump40. Recently, a 
novel AraC-type regulator known as regulator of antibiotic resistance A (RarA) was shown 
to upregulate AcrAB expression when E. coli was exposed to carbapenem157. Additionally 
mutations in other genes known to be involved in the export of proteins in E. coli might 
contribute in carbapenem resistant phenotype e.g. secDF158.  
Apart from carbapenem resistance, we did not see colistin resistance in this collection. 
Furthermore, we detected particular resistant clones known as high-risk clones e.g. ST131-
H30Rx/C2, ST410-H24RxC and ST1193-H64RxC. The latter was associated with NDM, to 
our knowledge for the first time in literature. In short, we confirm the hypothesis that resistant 
E. coli strains in Oman are similar to the international resistant clones and might in fact 
contribute to the emergence of clones with more resistance attributes such as ST1193-
H64RxC.  
4.1.2 K. pneumoniae : Paper II and Paper III 
Paper II presents the population structure and resistance mechanisms of carbapenem-non-
susceptible K. pneumoniae in Oman based on 218 strains selected from the initial 237 
examined isolates. Additionally,  in Paper III we studied particularly colistin-resistant K. 
pneumoniae (n=25).  
Analysis of genetic background revealed 22 STs of which two were novel (ST4547 and 
ST4548) and 14 were singletons. The most commonly seen STs were ST231 (32%) and ST11 
(31%), followed by ST147 (15%), ST15 (6%) and ST101 (5%). To visualize subclones, 
classical multidimensional scaling was performed based on SNP-distance matrix. ST11 could 
be further subtypes into three subclones; one localized in a single hospital (SQH), the second 
seen was in two hospitals (Khoula and Nizwa) whereas the third one was found in different 
hospitals. ST101 showed three subclones each one of them was linked to particular hospitals 
which  suggests local transmission events. ST231 was less diverse with no subclones 
observed, which  reflects that one clone was disseminated in the entire country (Figure 12). 
Regarding carbapenem resistance, 87% of the isolates harbored carbapenemase genes. We 
could not detect carbapenemases in 29 isolates, some of them (n=10) were putative MBLs-
producers according to the ROSCO phenotypic carbapenemase detection kit and were 
positive with Carba-NP (n=10). Similar to the pattern seen in E. coli, only NDM and OXA-
48-like family were detected in K. pneumoniae. This also aligns with published molecular 
data about CRE in Oman79,159. While NDM has been observed in different STs, ST231 is 
almost exclusively linked to OXA-232. This was also reported from other countries in the 
Arabian Peninsula such as Yemen and UAE as well as India160-162. This again links the 
resistance patterns in the Indian subcontinent and the Arabian Peninsula.   
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Another common observation between Indian subcontinent and the Arabian Peninsula, is the 
lack of KPC enzymes. KPC enzymes are usually associated with sequence types within clonal 
complex (CC258) such as ST258 or ST11. Despite ST11 was one of the major STs in this 
collection and was known to be associated with KPC epidemic in China, we did not detect 
KPC in this collection163-166. This is an interesting finding and requires further investigation 
to elucidate the reasons which undoubtedly will reveal much about biological evolution of 
antibiotic resistance. For example, what factors might contribute to the spread of this 




Figure 12. Population structure of carbapenem-non-susceptible K. pneumoniae. Based on SNP-distance matrix 
and MLST, we could identify five major sequence types (STs); ST231, ST11, ST147, ST15 and ST101 as 
presented in the inner circle. The coloured ring indicates the hospitals from where these isolates were obtained. 
Furthermore, based on classical multidimensional scaling, we saw two or three subpopulations in each major 
STs except ST231. Additionally, we saw low genetic diversity in ST231 which might suggest dissemination of 




Regarding colistin resistant strains (n=25), most belonged to ST231 (n=9) and ST11 (n=6) 
as they were the major STs in this collection. The mechanism of resistance could be attributed 
to genetic alteration in genes that regulate the two-component systems in K. pneumoniae such 
as PhoPQ , PmrAB and CrrAB. Mutations in pmrB gene were the commonest (n=19). To the 
contrary, only wild-type pmrA gene was detected in this collection. We did not either detect 
mcr gene in this collection. 
Another common colistin resistance mechanism is the presence of mutations in the mgrB, 
gene which encodes a negative regulator of PhoPQ system. We observed a frame shift at the 
9th codon (Ser9fs) of  mgrB in three strains. Apart from mutations in mgrB, the gene could 
be inactivated by insertion elements (ISs) which was detected in 8 isolates via three different 
insertion elements (ISs). Particularly, ISKpn14 as the commonest as it was seen in 6 isolates. 
In four of them ISKpn14 had identical insertion site as it disturbed mgrB at nucleotide 116 
by same direct repeat that suggest a close relation between these strains. Clinically, three of 
them (OM300, OM290, OM536) were obtained from the same hospital (Nizwa) whereas the 
fourth isolate (OM124) was obtained from a patient transferred from Nizwa hospital to 
Khoula hospital which suggests a root of transmission across the hospitals. Genetically, the 
strains belonged to ST11 and were clustered into two groups apart from each other  by 18 
SNPs. It is highly likely, the strains had common ancestor and presenting a cross hospital 
transmission.  
Apart from resistance genes to survive antibiotic treatment, the initial ability of K. 
pneumoniae to cause infections is determined to a large extend by its content of virulence 
factors. For example, the presence of  K2 capsule type, rmpA/rmpA2 and specific 
siderophores molecules (yersiniabactin and aerobactin) are associated with virulence in K. 
pneumoniae167,168. Here, K2 capsule was detected  in four carbapenemase producering 
strains. Also, yersiniabactin and aerobactin were detected in 73% and 26% of the strains, 
respectively. Additionally,  an ST2096 colistin resistant and OXA-232 producer strain 
(OM5488) harbored rmpA/rmpA2, aerobactin (iuc1) and yersiniabactin (ybt-14). Such clone 
was isolated recently from India and reported to cause an ICU (intensive care unit) outbreak 
in Saudi Arabia169,170. Clones with both resistance and virulence attributes are concerning 
since they have the ability not only to establish infection in immunocompromised individuals 
but also in healthy individuals.  
All in all, we confirm the hypothesis that population structure of resistant strains in Oman is 
similar to the international resistant clones such as ST131 in E. coli and ST11 in K. 
pneumoniae. However, we noticed newly emerging clones such as ST1193 in E. coli with 
carbapenemase gene. Also, a high prevalence of ST231 in K. pneumoniae was seen, which 
is not commonly observed in other regions. The most concerning is the presence of highly 
resistant and virulent clones such as ST2096. More about virulence is discussed in the 
following section.  
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4.2 Interaction of innate effectors with colistin resistant strains: Paper IV  
In Paper IV we aimed at investigating if there was a cross-resistance between colistin and 
LL-37. We examined this by time-kill assay and growth curve experiment. Additionally, we 
studied structural and intracellular changes induced by LL-37 against polymyxin resistant 
strain via electron microscopy. We looked into the genetic changes that confer resistance to 
polymyxin and its implication such as reduction of the net negative charge in outer 
membrane. Finally, we investigated bacterial fitness of the colistin resistant strains and how 
the innate effectors interact with them as well as how their survival in a zebrafish model.  
4.2.1 Interaction of colistin resistant strain with LL-37  
LL-37 is a component of the innate immune system and has a wide antimicrobial activity. 
Both colistin and LL-37 share similar binding mechanism to bacterial cell wall. As such the 
emergence of resistance against colistin might affect how bacteria interact with LL-37. We 
investigated if resistance to colistin induces high tolerance to LL-37. Additionally, we looked 
into intracellular and extracellular changes in bacterial cell when treated with LL-37 using 
electron microscopy. 
 4.2.1.1 Cross-resistance with LL-37  
Here, we studied how LL-37 interacts with two genetically similar strains yet differ in their 
susceptibility to colistin. OM124 gained resistance by inactivation of mgrB gene with  
insertion element whereas the susceptible strain (OM322) had an intact mgrB gene.  From 
the designed time-kill and growth curve experiments, we saw a cross-resistance between LL-
37 and colistin but only at a concentration higher than 50 mg/L (or 11.25 μM). Furthermore, 
similar finding was seen when more isolates (n=8) with mgrB insertion were included 
compared to colistin susceptible strains (n=9). However, only strains with mgrB-insertion 
were studied. The cross-resistance might be specific to this particular resistance mechanism. 
Published data were inconclusive regarding the cross-resistance hypothesis. In K. 
pneumoniae, Kadar et al., reported high tolerance to different antimicrobial peptides 
including lactoferrin and lysozyme67.However, Dobias et al. showed no difference in the 
interaction with LL-37 in colistin resistant K. pneumoniae stains due to different mechanisms 
including mgrB-insertion. Nevertheless, our data supported their finding as they examined 
LL-37 at concentrations ≤ 20 mg/L (or ≤ 4.5 μM)171. We have not seen cross-resistance at 
LL-37 concentration < 50 mg/L (or 11.25 μM). Regarding colistin resistance in Acinetobacter 
baumannii , Moffatt et al. reported a colistin resistant isolate due to an LPS-deficient mutation 
in the lpxA gene (deletion of a single base at nucleotide 90), which was more susceptible to 
LL-37 at  concentrations ≥ 5.5 mg/L (or  ≥ 1.25 μM) but no difference was observed below 
this concentration172. Yet, Garcia-Quintanilla showed no difference at a concentration of 3.13 
mg/L (or 0.7 μM) in a collection of resistant strains due to different mechanisms including 
lpxA mutation (I205N)173, which is aligned with the previous finding by Moffatt et at. despite 
the particular mutation in lpxA varied between the studied strains. The finding of  decreased 
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susceptibility to LL-37 in colistin resistant strain ≥ 5.5 mg/L by Moffatt et al. was 
contradicted by Napier et al. as they showed cross-resistance at a concentration of 6.25 mg/L 
( or 1.4 μM), though the mechanism of resistance was not mentioned60. Such discrepancies 
might be attributed to using variable methodology e.g. protocols regarding growth medium, 
incubation time, initial bacterial inoculum, LL-37 concentration and mechanism of resistance 
in the studied strains.  
The impact of cross-resistance on individuals depends on their health status. In a healthy 
individuals the concentration of LL-37 is estimated to be below 2 mg/L in serum and 
plasma174. Yet in individuals with autoimmune diseases such as psoriasis, LL-37 level in 
plasma could reach as high as 1,366 mg/L175.Thus, the ability of LL-37 to clear infection 
caused by colistin resistant strains is significantly reduced compared to infection caused by 
colistin susceptible strain. Also, neutrophil stores high concentration of LL-37 estimated to 
be 640 mg/L, which is released during inflammation to clear infection174. This implies the 
activity of LL-37 released from neutrophil to clear infection caused by colistin resistant strain 
is lower than that of colistin susceptible strains even in healthy individuals. However, the 
concern of using antimicrobial peptides as a therapeutic approach could compromise natural 
immunity might be overestimated59,176. Yet, evaluating cross-resistance to host AMPs in new 
therapeutic AMPs is highly desirable126-130. 
In summary, our data support there is cross-resistance between colistin and LL-37 but only 
at high concentration of  ≥ 50 mg/L (or ≥ 11.25 μM). This aligns with our knowledge that 
LL-37 has antimicrobial activity against Gram-positive bacteria which lack LPS and are not 
commonly treated with colistin177. Most likely the negativity of LPS in Gram-negative 
bacteria enhances LL-37 binding to bacterial cell but is not the only means of interaction. 
Next, we thought to complement this concentration dependence finding by further looking 
into the variation of cellular changes induced by different concentrations of LL-37 on 
bacterial cell as discussed in the following section. 
4..2.1.2 Extracellular and intracellular impact of LL-37 on bacterial cell 
Gram-negative bacteria undertake modification in the structure of their cell walls to gain 
resistance against colistin. Such changes might also interfere with how they interact with 
other molecules, including LL-37, compared to wild-type. In addition, the intracellular 
changes induced by LL-37 to eventually kill bacteria might be concentration dependence. To 
that end, we studied morphological changes induced by different concentrations of LL-37 
(50-200 mg/L) at different exposure time (0.5 and 2 h) via transmission electron microscopy 
(TEM) and scanning electron microscopy (SEM). Two genetically similar isolates differing 
in their susceptibility to colistin were included in this study.  
Intracellular changes were inferred from TEM images. Bacterial exposure of 100 mg/L 
induced morphological changes within 30 minutes of treatment. We observed clustering of 
DNA and ribosomes in both resistant and susceptible strains. Despite the resistant strain was 
less affected by LL-37 at concentration above 50 mg/L in CFU-counts that was performed in 
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parallel with TEM experiment. Worth noting, the isolates lost their capsules after exposure 
to LL-37 compared to the control untreated strains. Interestingly, using atomic force 
microscopy (ATM), Formosa et al. showed  that the capsule of polymyxin resistant K. 
pneumoniae due to mgrB inactivation was tightly bound to bacterial cell wall when exposed 
to polymyxin as well as it became harder as the concentration of polymyxin increased, while 
the strain with intact mgrB lost their capsule55. This implies mgrB alteration has an impact in 
capsule structure. Although we did not notice variation between the strains as they did. Also,  
since capsule has anionic  charge whereas LL-37 has cationic charge, the capsule could 
neutralise the killing effect of the peptide via electrostatic interaction and thereby reduce the 
amount of LL-37 that can reach bacterial cell wall as shown previously178.  
Changes in the surface structure were inferred from SEM images. Exposure to LL-37 (100 
mg/L) for 30 minutes turned both strains to appear more swollen compared to control 
untreated strains. This effect was more profound at higher concentration (200 mg/L) and 
exposure time (2 h).  
In summary, exposure to LL-37 had profound impact on both strains with no obvious 
differences between them. These data and the CFU-counts which were performed in parallel 
with TEM and SEM experiments, indicate resistance to colistin might affect the quantity but 
not the quality of changes induced into bacterial cell. As far as LL-37 manages to enter the 
cell, the morphological effects were neutral to resistance pattern. This also emphasizes in the 
ability of LL-37 to bind to resistant strain despite the changes induced by the genetic variation 
causing colistin resistance. Thus, we wonder if resistance mechanism against colistin indeed 
reduces the net negative charge or lead to other changes beside or apart from that.  
4.2.2 The mgrB-insertion did not impact surface charge  
It is commonly accepted that colistin resistance arises due to reduction of the net negative 
charge in LPS which is induced by genetic modification in genes regulating lipid A synthesis 
in Gram-negative bacteria. The hypothesis is supported by finding that showed reduced 
negativity in species known to be intrinsically resistant to colistin such as Proteus 
mirabilis150. Genomic analysis of the studied strains revealed the cause of colistin resistance 
to be due to mgrB-insertion by ISKpn14. We investigated if such genetic alteration might 
impact the surface charge via measuring zeta potential in two different media PBS and 
deionised water.  
Unexpectedly, the data showed no significant changes in the negativity of the studied strains 
(P=0.54 in DIW and P 0.99 ≥ in PBS). Similar finding was reported by Ayerbe-Algaba et al. 
as they studied colistin resistant strain due to mgrB-insertion as well179. However, our data 
contradict with what was reported by Velkov et al. They reported a reduction on the surface 
charge of K. pneumoniae that gained colistin resistance phenotype in vitro180. It could be that 
different mechanisms of resistance result in different structural or chemical changes in K. 
pneumoniae.   
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Colistin mechanism of action relies on two initial steps; the binding of the cationic drug to 
the anionic lipid A via electrostatic interaction and the insertion of the drug fatty acid tail or 
head group into the membrane via hydrophobic interaction. Consequently, resistance to 
colistin involves modification of lipid A structure mainly via the two-component systems 
PhoPQ and PmrAB. The alteration leads eventually to either reduction in the net negative 
charges which is achieved by different approaches e.g. addition of positively charged 
molecules (phospohethanolamine or aminoarabinose) or blocking LpxT to cease the  addition 
of phosphate groups. Another modification could not affect the surface charge but the 
hydrophobic interaction. This could be achieved by different mechanisms including addition 
of palmitate via PagP or acyl chain substitution by secondary acyl-transferases (lpxL and 
lpxM). K. pneumoniae encodes two LpxL homologoues LpxL1 and LpxL2. They are 
expressed at normal growth condition and both compete to add, at the same position,  a fatty 
acyl chain in lipid A  either a lauroyl or myristoyl group, respectively34. Lipid A in  K. 
pneumoniae differs from the E. coli only by the presence of myristoyl residue181. 
As the strains here showed no variation in the net negative charge, we speculate that bacteria 
could modify the hydrophobicity trait. This could be achieved by secondary acylation in K. 
pneumoniae. Published data showed an increase in sensitivity to antimicrobial peptides and 
colistin in lpxM-mutated (msbB/waaN) K. pneumoniae strain. The effect could be reverted 
when the mutation was complemented in vitro181. Additionally, Bordetella bronchiseptica is 
highly resistant to antimicrobial peptides compared to Bordetella pertussis which has been 
attributed to ArnT182. MgrB-insertion is known to induce ArnT indirectly by activating the 
two-component system PhoPQ. Thus, we hypothesize, mgrB truncation will indirectly 
activate ArnT that will promote acylation through yet unrecognised pathway. However, the 
genetic alteration might induce changes other components of LPS such as the O-antigen. 
Another distinctive genetic difference between the two studied isolates was the O-antigen. 
The resistant strain had O3b while the susceptible strain had OL104. Both are considered 
subgroups of O3 serotype. They varied only in wbdD gene183. Besides, we noticed that the 
susceptible strain lacked manB gene compared to the resistant strain, which is involved in 
monosaccharide synthesis183. This might lead to variation in the length of O-chain between 
the two strains. Additionally, Campos et al. showed that O-polysaccharides conferred 
resistance against polymyxin in K. pneumoniae in the absence of the capule184. Since both 
strains lost their capsules when treated with LL-37 as evident from TEM experiment, LL-37 
would probably interact with O-antigen directly. Also, Benemann et al. reported the presence 
of O-specific sugar side chains conferred resistance to antimicrobial peptides in B. 
bronchiseptica185. 
In summary, no reduction in surface negative charge due to mgrB-insertion was observed yet 
the two strains differed in O-antigen. We hypothesize resistance mechanism in the studied 
strain of K. pneumoniae could be similar to what is seen in B. bronchiseptica rather than in 
P.  mirabilis.  
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4.2.3 Pathogenicity and virulence of colistin resistant strains 
We investigated if gaining colistin resistance implies fitness cost by exposing the strains to 
blood and serum following by CFU-counts. We noticed no difference in fitness and 
survival rate in both strains. Moreover, we studied the strains survival in zebrafish. 
Similarly, we did not see significant difference in their survival. We conclude mgrB 
truncation in K. pneumoniae do not affect bacterial fitness.  
In short, we rejected the hypothesis that there is fitness cost which bacteria pay to gain 
resistance trait as no variation seen in both colistin resistance and colistin susceptible 
isolates. To the contrary, bacteria gain tolerance to LL-37 free of cost.   
4.3 Impact of combination therapy onto resistant strains 
We studied options to treat infections caused by resistant strains. In paper III for K. 
pneumoniae and in Paper V for E. coli. We achieved this by setting a time-kill assays with 
the combination of the drugs and looked into CFU-count. 
4.3.1 Combination therapy in E. coli: Paper V 
In this paper we examined the impact of polymyxin B in combination with aztreonam, 
meropenem, minocycline and rifampicin against 20 carbapenemase producing E. coli strains. 
We found synergistic effect between polymyxin B with minocycline as well as between 
polymyxin B with rifampicin against 11 or 9 isolates, respectively. Interestingly, we saw a 
correlation between the presence of tet(B) gene and wildtype soxR gene and the outcome of 
polymyxin and minocycline combination. Besides, aztreonam or meropenem with polymyxin 
B showed synergistic effect in 2 out of 20 strains. We could not see any synergistic effect 
between meropenem or aztreonam with polymyxin.  
4.3.2 Combination therapy in K. pneumoniae : Paper III 
We looked into the activity of colistin with rifampicin or azithromycin as a treatment option 
for colistin and carbapenem resistant K. pneumoniae strains (n=25). We saw synergistic 
effect (≥ 1 log10 reduction) with colistin and rifampicin while we saw an additive effect with 
azithromycin (≥ 1 log10 reduction). Both azithromycin and rifampicin antibiotics target 
intracellular components of bacterial cell while colistin target cell wall. Colistin will expose 
bacterial cell to the other antibiotics and enhance their activities.  
In summary, rifampicin in combination with polymyxin was the best combination in vitro 









The main findings from this thesis could be summarised as below: 
 
 
I. Oman as being part of the Arabian Peninsula has high prevalence of NDM and 
OXA-48 carbapenemases mirroring the antibiotic pattern seen in the Indian 
subcontinent. We identified international high-risk clones including ST131 in E. 
coli and ST11 in K. pneumoniae as well as the potential of newly emerging high-
risk clones such as ST1193-H64RxC in E. coli and ST231 in K. pneumoniae. 
 
II. Colistin resistance did not imply cost of fitness or redcuction in bacterial 
pathogencity at least in K. pneumoniae with mgrB-insertion. To the contrary, the 
resistant bacteria tolerate high concentrations of LL-37 (≥ 50 mg/L or ≥ 11.25 
μM). Thus, having the advantage to escape one of the innate immunity free of cost.  
 
III. There is no reduction in the surface charge of colsitin resistant K. pneumoniae with 
mgrB-insertion. Suggesting the genetic alteration in mgrB gene might interfer with 
other chemical or structural changes e.g. O-antigen or hydrophobicity. 
 
IV. Rifampicin combined with polymyxin E (colistin) showed good in vitro activity 
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